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1. Introduction 
 
The present study investigated the role of c-Jun-N-terminal kinases (JNKs) in cell death and 
in differentiation. In PC12 cells, 6-hydroxy-dopamine (6-OHDA) induced death was 
attenuated by the JNK-inhibitor SP600125 and transfection of dominant negative JNK2. The 
JNK2, but not JNK1 isoform, translocated to the nucleus and the mitochondria after 6-OHDA 
treatment where it exerted its apoptotic functions. Besides PC12 cells, the function of JNKs 
was also investigated in primary hippocampal and cortical neurons, where JNKs have both 
apoptotic and physiological functions. 
 
1.1 Mitogen-activated protein kinases (MAPKs) 
 
Mitogen-activated protein kinases (MAPKs) are important mediators for intracellular 
signalling. MAPK cascades are evolutionarily conserved in all eukaryotic cells and play a key 
role in the regulation of gene expression as well as cytoplasmic activities [1]. To date four 
major types of MAPK pathways have been defined in mammalian cells. These include the (i) 
extracellular signal-regulated kinase 1 and 2 (ERK1/2) cascade which preferentially regulates 
cell growth and differentiation, (ii,iii) the c-Jun N-terminal kinase (JNK) and p38 MAPK 
cascades, which function mainly in stress responses like inflammation and apoptosis, and 
finally (iv) the  ERK5 cascade, which is activated by environmental stress and osmotic shock, 
but not by vasoactive peptides or inflammatory cytokines [1-3]. All MAP kinases are 
serine/threonine kinases that are activated in response to their phosphorylation on invariant 
threonine (Thr) and tyrosine (Tyr) residues within a Thr-X-Tyr motif (where X is any amino 
acid). This phosphorylation is catalysed by MAPK kinases (MAP2Ks, MEKs, MKKs), which 
in turn, are activated by MAPK kinase kinases (MAP3Ks) via serine/threonine 
phosphorylation. MAP3Ks receive signals from cell surface receptors through a variety of 
intermediates, including other protein kinases and small GTP binding proteins (reviewed by 
[3-6]) (Fig. 1.1). Importantly activation of MAPKs leads to phosphorylation of other kinases 
or transcription factors that activate a variety of response genes [3]. 
 
Among the four types of MAPK pathways, the present thesis focused at the c-Jun N-terminal 
kinase (JNK) pathway. 
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1.2. The organization of c-Jun N-terminal kinases (JNKs) 
 
Ten isoforms of JNK are expressed in human adult brain. These ten isoforms are encoded by 
three genes: jnk1, jnk2 and jnk3. The jnk3 gene is preferentially expressed in the heart, 
pancreas, brain and testis, while jnk1 and jnk2 are expressed in many tissues [7-10]. 
Alternative splicing of the genes yields four JNK1 isoforms, four JNK2 isoforms and two 
JNK3 isoforms. The protein products of JNK isoforms have molecular weights of 46 kDa and 
55 kDa. The 55 kDa JNK isoforms contain a C-terminal extension, the result of alternative 
splicing, which distinguishes them from 46 kDa isoforms. No apparent functional differences 
have been ascribed to these isoforms. An additional alternative splicing exists in the kinase 
domains of JNK1 and JNK2 but not in JNK3. JNK1 and JNK2 have significant functional 
differences particularly in regard to substrate binding [7]. 
 
The JNK pathway is one of the known cellular signalling pathways that respond to much 
diverse stimuli. JNK is activated by mitogenic signals such as epidermal growth factor, 
lymphocyte activation signals and oncogenic Ras, pro-inflammatory cytokines such as TNF-α 
and IL-1, lipopolysaccharide, osmotic stress, shear stress and protein synthesis inhibitors. 
JNK is also activated by apoptotic stimuli such as growth factor withdrawal, ischemia, 
ceramides, UV light, oxidative stress and DNA damaging agents [3, 7, 10-12]. 
 
The JNKs are phosphorylated and activated by MAP2Ks, MKK4 and MKK7, which 
phosphorylate JNK1 and JNK2 on their Thr 183 and Tyr 185 residues and JNK3 on Thr 221 
and Tyr 223 residues. These kinases in turn are activated by MAP3Ks, of which several 
examples have been identified such as, MEKK1-4, ASK1, TAK1, MLKs or the GTP-binding 
proteins of the Rho family, Rac and cdc42 [3, 6, 13]. JNK activities can be down-regulated by 
protein phosphatases, including M3/6 and MKP-1. These phosphatases display selectivity 
toward JNK family members [14, 15]. An additional level of control of the JNK signalling 
pathway is provided by JNK-interacting proteins (JIPs). These are scaffold proteins that 
mediate the signal transduction through MLK, MKK and JNK pathways. The JIPs can 
antagonize the JNK actions by recruiting the MAPK phosphatase MKP7 with subsequent 
dephosphorylation and inactivation of JNKs [16] or by retention of JNKs in the cytoplasm 
[17].  
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Many substrates are phosphorylated by the JNKs including the transcription factors c-Jun, 
ATF2, Elk-1, NFAT, as well as tumour suppressor p53 and a cell death domain protein, 
MADD. Additionally, cytoplasmic targets such as the neurofilament heavy unit, Bcl-2 and tau 
serve as JNK substrates [6, 18, 19].  
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Fig. 1.1. The organization of the p38 and JNK system of MAP kinases 
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1.3. JNKs as mediators of neurodegeneration 
 
Numerous experimental data suggest a pro-degenerative or apoptotic function for the JNKs 
[20-22]. JNKs trigger neuropathological events, e.g. after trophic support withdrawal in 
sympathetic neurons [23-25] or cerebellar neurons [26, 27], delayed ischemic cell death [28, 
29], excitotoxicity [30] or in models for Alzheimer’s disease [31] and Parkinson’s disease 
[32-36]. 
 
1.3.1 Mitochondria-induced death 
 
Mitochondrial dysfunctions are central to the pathogenesis of neurodegenerative diseases such 
as Alzheimer’s, Parkinson’s or Huntington’s diseases [37], and are important for neuronal 
excitotoxicity [38]. JNKs translocate and associate with the mitochondria [39] where they 
inactivate anti-apoptotic and promote pro-apoptotic proteins of the Bcl-2 family such as Bcl-
2, Bcl-xL, Bad, Bim or Dp5 [40-44]. Moreover JNKs release inhibitors of anti-apoptotic 
proteins, such as Smac/Diablo from the mitochondria [45]. In fibroblasts, UV irradiation 
provoked apoptosis, caspase-3 activation and cytochrome c release from mitochondria due to 
JNK presence, whereas in jnk1-/- jnk2-/- fibroblasts, UV irradiation did not cause cytochrome 
c release and caspase-3 activation [46]. When the constitutively active form of apoptosis 
signal-regulated kinase 1 (ASK1, JNK activating kinase) was transiently expressed in vitro, it 
induced apoptotic cell death [47] and cytochrome c was released from mitochondria [48]. 
These results demonstrate that JNKs are involved in the mitochondrial apoptotic pathways. 
However, it remains to be elucidated which JNK isoform(s) mediate(s) the mitochondrial 
pathology. 
 
1.3.2. Induction of death genes 
 
Besides mitochondrial apoptotic pathways, JNKs activate transcription factors in the nucleus, 
such as c-Jun, ATF-2 or Elk-1. In the nervous system, JNKs are involved in the transcription 
of pro-apoptotic target genes coding for Fas-ligand, TNFα or Bim [41, 49]. The activation of 
transcription factors might be exerted by JNK2 and JNK3 which rapidly translocate into the 
nucleus whereas the basal constitutive presence of activated JNK1 in the nucleus is not 
effective in phosphorylation of transcription factor such as c-Jun [26, 27, 50]. 
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JNK3 deficient mice (JNK3 -/-), but not JNK1 -/- and JNK2 -/-, and mutation of the serine 
residues 63 and 73 into non-phosphorylable alanins (c-JunAA mutant) show increased 
resistance to kainic acid induced seizures and to death of hippocampal neurones [30, 51]. 
JNK3 mutant mice also show a severe defect in phosphorylation of c-Jun and the 
transcriptional activity of the AP-1 transcription factor complex [30]. Moreover, in culture, 
functional inhibition of c-Jun by microinjection of antibodies or dominant negative c-Jun 
protects neonatal sympathetic neurons from NGF withdrawal-mediated neuronal cell death 
[52, 53]. These results suggest that JNK and c-Jun transduce the cell death signal at least 
partially through transcription-dependent machinery in neurons. 
 
1.3.3. Degeneration of dopaminergic neurons  
 
JNKs are also essential mediators of neurodegeneration provoked by oxidative and/or radical 
stressors e.g. MPTP or 6-OHDA, which are hallmarks of Parkinson’s disease. MPTP induced 
neuronal damage is accompanied by activation of JNKs and MKK4 in the substantia nigra 
compacta [54]. Importantly, MPTP-induced cell death and JNK activation in dopaminergic 
neurons can be effectively reduced in rats by administration of the MLK-antagonist and 
indirect JNK-inhibitor, CEP-1347 [36] and in mice by administration of specific JNK-
inhibitor SP600125 [55]. Furthermore, expression of the JNK-binding domain of JIP-1 or of a 
dominant-negative MKK4 attenuated both, the dopaminergic neuronal death and the 
activation of JNK and c-Jun following MPTP exposure [56]. However, all JNK isoforms do 
not contribute equally to stress-induced dopaminergic cell death. Deletion of jnk2/jnk3, but 
not jnk1, genes suppressed MPTP-induced phosphorylation of c-Jun and attenuated MPTP-
induced dopaminergic cell death in vivo [34]. Similarly, our group showed that JNK3 ko and 
c-JunAA mutation conferred cell-specific protection of dopaminergic neurons whereas JNK1 
ko enhanced the damage following ischemia [57]. 
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1.4. Physiological functions of JNKs 
 
Expression and activation of JNK and c-Jun in the mammalian adult brain in the absence of 
any harmful stimulus or in neuronal cell cultures during differentiation suggest important 
physiological/protective roles for JNK and c-Jun (reviewed by [21]). To understand the 
physiological functions of JNKs in the nervous system, their roles in development, 
neuroplasticity and neurorepair has to be explained. 
 
JNKs are imperative for the physiological normal development of the nervous system. Thus, 
double knock out of JNK1 + JNK2 results in embryonic lethality due to failed closure of the 
neuronal tube [58]. Moreover, JNK1-/- JNK2 -/+ or JNK1 -/+ JNK2 -/- mice display distinct 
malformations in the brain [59]. The activities of JNKs and MKK4/7 in the forebrain rise after 
birth, indicating a role of JNKs in postnatal maturation [26]. Importantly, JNK1 is required for 
the maintenance of neuronal microtubules, and JNK1-/- mice display anatomical 
malformations and neurodegeneration such as disrupted formation of the anterior tract 
commissure which becomes evident within the first weeks after birth [60]. The truncated 
JNK3 (trJNK3, i.e. the terminal 273 amino acids) as the only identified genetic alteration 
occurs in children with early severe neurological symptoms such as drug-resistant seizures, 
cognitive deficits and neuronal degeneration (Kalscheuer and Ropers, oral communication). 
In addition, deficiency of the JNK target c-Jun resulted in a severe proliferation defect in 
fibroblasts and /or in hepatoblasts of c-Jun knockout mice [61, 62]. Thus, at least in cultured 
fibroblasts and hepatoblasts, c-Jun acts as a positive regulator of cell growth. Moreover, mice 
lacking c-Jun survive only to embryonic day 12 and die due to massive hemorrhage in the 
liver, suggesting physiological roles of the JNK/c-Jun axis (reviewed by [63]). 
 
Besides the embryonic development, JNKs exert important functions on the re-arrangements 
of neuronal cytoskeleton such as differentiation, neuronal plasticity and neuroregeneration. 
JNKs can phosphorylate actin, tau, neurofilament, MAP-1 or MAP-2, and thereby alter the 
cytoskeletal functions [60, 64, 65]. The functional deletion of JNK1, but not JNK2, provokes 
a progressive loss of microtubules in axons and dendrites [60]. JNKs have also essential 
functions for the differentiation of neurons. MKK7 and JNK activity increase during 
neuritogenesis in primary cerebellar granule neurons [26] and inhibition of JNKs dramatically 
reduced axonal outgrowth in explanted or dissociated ganglia [66]. Similarly, c-Jun and JNKs 
may also contribute to NGF induced neurite outgrowth in PC12 cells [67]. 
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In addition to cytoskeletal functions and differentiation JNKs play important roles in 
neuroregeneration and neuroprotection. JNK activation is sustained in dorsal root ganglia 
after axotomy in regenerating neurons and returns to basal levels after the regeneration 
process has been completed [68, 69]. JNKs and their nuclear substrate c-Jun are considered 
important mediators of the regenerative cell body response [54, 70, 71]. Besides 
neuroregenerative effects, JNKs may promote cell survival. Immature thymocytes and 
peripheral mature T cells deficient in jnkk1 (sek1/mkk4) were highly susceptible to Fas/CD95- 
and CD3-mediated apoptosis suggesting that JNKK1 may play an anti-apoptotic role in T 
cells [72]. Biochemical analysis also revealed that activation of JNKs may be involved in 
suppression of apoptosis in B lymphocytes through phosphorylation and inactivation of the 
pro-apoptotic molecule Bad [73]. 
 
1.5. Inhibition of JNKs as a therapeutic strategy 
 
JNKs play an integral role in neuronal death and this pathway might be operative in several 
diseases of the central nervous system. Neuroprotection by inhibition of JNKs may offer an 
attractive strategy for prevention of the neuronal death. However, the potentially relevant 
physiological functions of the JNKs might limit the use of antagonists as a novel strategy for 
therapy. For example, given the important role of JNK1 in the maintenance of neuronal 
microtubules or plasticity [60], it is important to avoid complete JNK inhibition. Due to the 
high similarity of JNK isoforms, the possibility of developing isoform-specific inhibitors is 
difficult. Moreover, inhibition of all or one JNK isoform(s) is not restricted to neurons, but 
may also affect other cells which contribute to brain integrity such as microglia [74]. 
 
The indirect JNK-inhibitor CEP-1347 originally called KT7515 [75] (3,9 bis 
[(ethylthio)methyl]-K252a), which primarily acts as a MLK inhibitor, has already entered 
phase II-III trials for treatment of Parkinson’s disease (www.parkinson-study-group.org). The 
mixed JNK-p38 inhibitor CNI-1493 which is currently applied in the inflammatory Cohn’s 
disease [76], attenuates neuroinflammation in the rat nervous system following neuropathic 
pain [77]. SP600125 (anthrax [1,9-cd] pyrazol-6(2H)-one), another direct JNK-inhibitor, also 
displays an effective anti-inflammatory potential in rheumatoid arthritis in rats [78] and in 
primary rat microglia [74]. This anti-inflammatory activity will enlarge the operative range of 
JNK-inhibitors in the nervous system providing further protection e.g. against Alzheimer’s 
and Parkinson’s disease [79]. 
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In addition,  jnk1-/- mice have been shown to be significantly protected from obesity-induced 
insulin resistance ([80], reviewed by [81]) suggesting that JNK is a potential therapeutic target 
for obesity and type-2 diabetes. The JNK-inhibitor SP600125 reduces bronchoalveolar 
accumulation of eosinophiles and lymphocytes in animals subjected to repeated allergen 
exposure, and reduces serum immunoglobulin E levels, indicating its possible use in treatment 
of asthma [82]. Finally, JNK pathway may provide tumour suppression in mice and human 
[83-85]. 
 
Because of the cross-talk within MAPK signalling cascade, as well as its cell-type and 
response-specific modulation, it is difficult to predict the potential adverse effects that might 
arise from the inhibition of the pathway. Numerous experiments are needed to achieve 
specific therapeutic outcomes without substantial side-effects. 
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A
B
 
 
 
 
Fig. 1.2. Chemical inhibitors of the JNK pathway 
A. CEP-1347, originally called KT7515 (or 3,9 bis [(ethylthio)methyl]-K252a), was identified in a 
medicinal chemistry approach directed to retain the desirable properties of the naturally occurring 
compound K252a whilst minimising any undesirable effects. B. SP600125, (anthrax [1,9-cd] pyrazol-
6(2H)-one], was defined by screening of a proprietary diversity library. SP600125, acted as a 
reversible ATP-competitive inhibitor of equal potency towards three JNK gene products, JNK1, JNK2 
and JNK3. 
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1.5. Scientific aims of the present study 
 
The present thesis studied neurodegenerative and physiological functions of JNK isoforms in 
PC12 cells and in primary neurons. For degeneration, 6-OHDA was used as inductor of 
neuronal death and experimental model for the degeneration of dopaminergic neurons 
underlying Parkinson’s disease. This study investigated the following questions: 
 
1. How does 6-OHDA affect the cell survival, the activation of JNK and the activation of 
its nuclear transcription factor c-Jun? 
 
2. Does the specific JNK-inhibitor SP600125, protect PC12 cells from 6-OHDA-induced 
death? 
 
3. Which JNK isoform(s) is/are important for the 6-OHDA-induced death in PC12 cells? 
 
4. Does 6-OHDA change the association of JNK with mitochondria? 
Which JNK isoform(s) do(es) mediate the mitochondrial-triggered death following    
6-OHDA including cytochrome c release and caspase-3 activation? 
 
5. Which upstream kinases are involved in the pro-degenerative role of JNK at the 
mitochondria? 
 
6. The JNK/c-Jun axis plays an important role in neuronal excitotoxicity. Primary 
hippocampal and cortical neurons were analyzed for the excitotoxicity of glutamate 
and 6-OHDA, respectively. Do JNKs mediate the excitotoxicity-induced death in 
primary neurons? 
 
7. Does inhibition of JNKs also interfere with the neurite outgrowth in primary neurons, 
as basic and relevant function for the neuronal differentiation and development of the 
nervous system?  
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2. Material and methods 
 
2.1. Materials 
 
Unless otherwise indicated, all solutions and dilutions were prepared in double-distilled water 
(DDW). All chemicals were pro analysis (p.a.). Apart from antibodies Table 2.1 gives all 
materials used in this study. 
 
Table 2.1. Materials 
Material Manufacturer / Supplier 
ABC kit Alexis; Grünberg, Germany 
Acrylamide / bis-acrylamide solution 29:1 Bio-Rad; München, Germany 
Agarose SeaKem LE Biozym; Oldendorf, Germany 
6-Aminocaproic acid Merck-Schuchardt; Hohenbrunn, Germany 
Ammonium persulphate (APS) Merck; Darmstadt, Germany 
Albumin, bovine fraction Sigma ;München, Germany 
Boric acid Merck; Darmstadt, Germany 
Bovine serum albumin (BSA) Boehringer; Mannheim, Germany 
Bromophenol blue Merck; Darmstadt , Germany 
B-27 Supplement Invitrogen/Gibco; Karlsruhe, Germany 
Calcium chloride Merck; Darmstadt, Germany 
Cell culture plates (3.5 cm) Sarstedt; Nümbrecht, Germany 
Cell culture plates (10 cm, 6 wells, 24 wells) Nunc; Karlsruhe, Germany 
Chamber slides Nunc; Karlsruhe, Germany 
Cover glasses Nunc; Karlsruhe, Germany 
Cryotubes (2 ml) Greiner; Frickenhausen, Germany 
Cytosine-ß-D-arabinofuranoside Sigma; München, Germany 
Cytotoxicity detection kit (LDH) Roche; Mannheim, Germany 
DAB tablets Sigma; München, Germany 
Dimethylsulfoxide (DMSO) Merck; Darmstadt, Germany 
DNAse Sigma; München, Germany 
dNTP set (10 mM solutions) Invitrogen/Gibco; Karlsruhe, Germany 
DTT 0.1 M Invitrogen/Gibco; Karlsruhe, Germany 
Dye Reagent Biorad; München, Germany 
Materials and methods 
 17
ECL Plus Amersham Biosciences; Freiburg, Germany 
EDTA Merck; Darmstadt, Germany 
EGTA Merck; Darmstadt, Germany 
Ethanol p. a. Merck; Darmstadt, Germany 
Ethanol, technical (denatured) Bundesmonopol für Branntwein (BfB); 
Offenbach, Germany 
Ethidium bromide solution (10 mg/ml) Invitrogen; Karlsruhe, Germany 
Fetal calf serum (FCS) Bio Whittaker; Vervriers, Belgium 
Filter paper Whatman; Maidstone, UK 
Filter unit 0.22 µm, syringe-driven Qualilab; Bruchsal, Germany 
Formaldehyde Merck; Darmstadt, Germany 
Gentamycin Invitrogen/Gibco; Karlsruhe, Germany 
G 418, sulphate (solution) Stratagene; Amsterdam, The Netherlands 
Glucose Merck; Darmstadt, Germany 
Glutamate Sigma; München, Germany 
Glutamax Invitrogen/Gibco; Karlsruhe, Germany 
Glycerol Merck; Darmstadt, Germany 
Glycine Merck; Darmstadt, Germany 
Hank’s balanced salts Sigma; München, Germany 
HEPES Merck; Darmstadt, Germany 
Hoechst 33258 Sigma; München, Germany 
Horse serum Invitrogen/Gibco; Karlsruhe, German 
Hyperfilm ECL Amersham Biosciences; Freiburg, Germany 
Immobilon P 1500 Millipore; Eschborn, Germany 
Insulin Sigma; München, Germany 
Kaiser’s glycerol gelatine Merck; Darmstadt, Germany 
Light antifade kit Molecular probes; Oregon, USA  
Magnesium chloride (PCR) Invitrogen/Gibco; Karlsruhe, Germany 
Magnesium chloride Merck; Darmstadt, Germany 
Magnesium sulphate Sigma; München, Germany 
2-Mercaptoethanol Sigma; München, Germany 
Methanol Merck; Darmstadt, Germany 
Microtiter plates, 96-well, round bottom, lid Nunc; Karlsruhe, Germany 
Minimum essential medium (MEM)  Sigma; München, Germany 
NGF (2.5 S) Alomone labs; Jerusalem, Israel 
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Non-fat dry milk Uelzena; Uelzen, Germany 
Nonidet P-40 Fluka Chemie; Buchs, Switzerland 
Oligo(dT)-Primer Invitrogen/Gibco; Karlsruhe, Germany 
Paraformaldehyde Merck; Darmstadt, Germany 
PBS (w/o Ca2+ and Mg2+) Invitrogen/Gibco; Karlsruhe, Germany 
PCR buffer (10 x) Invitrogen/Gibco; Karlsruhe, Germany 
pEGFP-C3 Clontech; Heidelberg, Germany 
Penicillin/Streptomycin solution (10,000 IU / 
10,000 µg/ml) 
Invitrogen/Gibco; Karlsruhe, Germany 
pGEMT Easy Promega; Mannheim, Germany 
Phosphatase Inhibitor Cocktail II Sigma; München, Germany 
Pipettes (serological, sterile; 5 / 10 / 25 ml) Sarstedt; Nümbrecht, Germany 
Pipette tips (10 / 200 / 1,000 µl) Sarstedt; Nümbrecht, Germany 
PMSF Sigma; München, Germany 
Poly-l-Lysine Sigma; München, Germany 
Ponceau S Sigma; München, Germany 
Potassium chloride Merck; Darmstadt, Germany 
Potassium dihydrogen phosphate Merck; Darmstadt, Germany 
Potassium disulphate Merck; Darmstadt, Germany 
Protease Inhibitor (Complete) Roche; Mannheim, Germany 
Protein marker, prestained, broad range New England Biolabs; Frankfurt, Germany 
Total RNA isolation kit NucleoSpin; Germany 
RNAse H Invitrogen/Gibco; Karlsruhe, Germany 
RPMI-1640 medium Invitrogen/Gibco; Karlsruhe, Germany 
SDS-PAGE standards, prestained, broad 
range 
Bio-Rad; München, Germany 
Sodium bicarbonate Sigma; München, Germany 
Sodium carbonate Sigma; München, Germany 
Sodium chloride Merck; Darmstadt, Germany 
Sodium dodecyl sulphate Merck; Darmstadt, Germany 
Sodium hydrogen carbonate Sigma; München, Germany 
di-Sodium hydrogen phosphate Merck; Darmstadt, Germany 
Sodium hydroxide Merck; Darmstadt, Germany 
SP600125 Alexis; Grünberg, Germany 
SuperScript Invitrogen/Gibco; Karlsruhe, Germany 
Materials and methods 
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Sucrose Sigma; München, Germany 
TEMED Carl Roth; Karlsruhe, Germany 
TdT enzyme Roche; Mannheim, Germany 
Thermanox coverslips Nunc; Karlsruhe, Germany 
TransFast  Promega; Mannheim, Germany 
Transferrin Calbiochem; Schwalbach, Germany 
Tris Merck; Darmstadt, Germany 
Triton X-100 Merck; Darmstadt, Germany 
Trypan blue solution, cell culture tested Sigma; München, Germany 
Trypsin Sigma; München, Germany 
Trypsin inhibitor Sigma; München, Germany 
Tubes (0.5 / 1.5 / 2.0 ml) Sarstedt; Nümbrecht, Germany 
Tubes for PCR  Sarstedt; Nümbrecht, Germany 
Tubes, sterile (15 / 50ml) Sarstedt; Nümbrecht, Germany 
Tween-20 Calbiochem; Schwalbach, Germany 
Ultrapure water Biochrom; Berlin, Germany 
6-hydroxy-dopamine Sigma; München, Germany 
 
2.2. Laboratory Equipment 
Table 2.2. Equipments 
Equipment Manufacturer / Supplier 
Agarose gel electrophoresis Bio-Rad; München, Germany 
AnalySIS software  Soft Imaging System; Münster, Germany 
Autoclave DS 202 Webeco; Bad Schwartau, Germany 
Centrifuge; Biofuge fresco, Labofuge GL, 
Megafuge 1.0 R 
Heraeus; Hanau, Germany 
Centrifuge; Mikrofuge Neolab; Heidelberg, Germany 
Cell incubator Heraeus; Osterode, Germany 
DMR microscope Leica; Solms, Germany 
Electrophoresis power supply Invitrogen/Gibco; Karlsruhe, Germany 
Film processor AGFA; Mortsel, Belgium 
Fluorescence microscope Leica; Solms, Germany 
Hemocytomer twin chamber Omnilab; Hamburg, Germany 
Heating block  (Thermomixer 543) Eppendorf; Hamburg, Germany 
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Incubator (Innova 4000) New Brunswick Scientific; Amsterdam, The 
Netherlands 
LeicaQwin software Leica; Solms, Germany 
Microplate reader 680 Bio-Rad; München, Germany 
MiniProtean II Vertical PAGE chamber Bio-Rad; München, Germany 
Olympus CK 2 microscope Olympus; Hamburg, Germany 
pH meter WTW; Weilheim, Germany 
Rotator (Polymax 2040) Heidolph; Kehlheim, Germany 
Semi-dry transfer unit (Pegasus) Phase; Lübeck, Germany 
Sonicator (Sonopuls GM 70) Bandelin; Berlin, Germany 
Spectrophotometer (U-2000) Hitachi; Wiesbaden, Germany 
Thermocycler (Personal Cycler) Biometra; Göttingen, Germany 
UV light (Image Master VDS) Bio-Rad; München, Germany 
Water bath Heraeus; Osterode, Germany 
 
2.3. Culture, staining and stimulation of PC12 cells 
 
2.3.1. Standard cell culture 
 
Medium 
RPMI-1640 medium 
Horse serum (HS, inactivated at 56° C for 30 min)  10% 
Fetal calf serum (FCS, inactivated at 56° C for 30 min) 5% 
Penicillin/Streptomycin     1% 
 
The rat PC12 pheochromocytoma cell line derives from a transplantable rat 
pheochromocytoma [86]. PC12 cells were purchased from the American Type Culture 
Collection (Manassas, VA, USA). The cells were grown in medium described above. The 
penicillin/streptomycin solution, horse serum and FCS were stored at –20° C, and the RPMI-
1640 medium was stored in a cooling chamber (4° C). The cells were cultured in 10 cm or 20 
cm plates according to the experiments. Twenty cm plates were used for mitochondrial 
extractions and 10 cm plates were used for the other experiments. Ten cm plates were filled 
with 7 ml medium and 20 cm plates were filled with 14 ml medium. The cells were fed every 
2-3 days. 
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PC12 cells, like many other adherent cells, need a structured substrate for growing. Therefore, 
all plates used for cultivation and experiments were coated with collagen (0.1 mg/ml in PBS). 
The bottom of the cell culture plates was covered with a thin layer of collagen solution, placed 
in the incubator for 1 h and then washed with PBS to remove collagen that had not adhered to 
the plate. Air-dried plates were stored under sterile conditions. 
 
2.3.2. Passaging of PC 12cells 
 
Passage-EDTA 
PBS   1x 
EDTA   0.5 mM 
Store at 4°C. 
 
Since PC12 cells grow adherent, they were treated with passage EDTA before passaging to 
reduce cell-substrate adhesion. 
 
Passaging of PC12 cells was maintained according to the following procedure: 
1. The cells were washed with PBS (37° C). 
2. The cells were rinsed with 2 ml passage-EDTA (37° C) and placed for 2 min in the 
incubator (37° C, 5% CO2). 
3. 5 ml of medium was added (37° C). 
4. The cells were scraped off the cell culture plate and transferred into a 15 ml tube. 
5. The cells were centrifuged for 10 min; (1000 xg; r.t.). 
6. The pellets were first resuspended with 2 ml of medium and then resuspended with 5 
ml of medium. 
7. The cells were aliquoted into new cell culture plates according to the diameter of the 
cell culture plate and the density. 
 
2.3.3. Freezing and thawing of PC12 cells 
 
Freezing medium 
RPMI-1640 supplemented with HS, FCS and pen/strep. (see 2.3.1) 80% 
FCS          10% 
DMSO         10% 
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PC12 cells were stored in aliquots at -80°C. When the cells had been passaged 20 times, the 
cells were discarded and a stock aliquot was quickly thawed in a 37° C water bath. The cell 
solution was transferred to a 10 cm plate with medium. Since DMSO is toxic for the cells, the 
medium had to be changed within the first 24 hours. After that, the cells were fed every 2-3 
days, passaged and used for the experiments. 
 
For production of PC12 stock aliquots, cells were harvested and pelleted as described in 
section 2.3.2 and resuspended in 1 ml freezing medium. The cell solution was aliquoted in 2 
ml cryotubes and incubated 10 min at r.t., transferred to ice for 35 min, incubated at -20° C 
for 45 min and finally stored at -80° C. 
 
2.3.4. Differentiation of PC12 cells 
 
(-) Serum Medium 
RPMI-1640 medium 
FCS    0.5% 
Penicillin/streptomycin 1% 
 
In response to NGF, growth arrest is induced and PC12 cells differentiate into neuron-like 
cells with formation and elongation of neurites. 
 
PC12 cells were passaged as described (See 2.3.2) and cultured in growth medium. After 24 
h, the cells were fed for 72 h with [-] serum medium to synchronize the cell cycle activity of 
the cells. After 72 h, the medium was changed and the cells were incubated with 50 ng/ml of 
NGF. The differentiating cells were fed with fresh medium containing NGF every 2–3 days. 
After 7 days of NGF treatment the cells were used for the experiments. 
 
2.3.5. Stimulation of PC12 cells 
 
In this study 6-OHDA was used for oxidative stress. 6-OHDA (10, 25, 50, 100 µM) was 
freshly prepared from 10 mM stock solution which was prepared in ascorbic acid solution to 
prevent oxidation. The cells were incubated with the JNK-inhibitor SP600125 (1, 2 µM) 30 
min before addition of 6-OHDA. After the respective incubation periods, RNA or proteins 
were extracted.  
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2.3.6. Trypan blue viability staining 
 
Various manipulations of cells, including passaging, freezing and stimulations may provoke 
cell death. To determine the number of surviving cells in a given population, exclusion of the 
dye trypan blue was used. Healthy cells are able to exclude this dye for a certain time, but 
trypan blue will quickly diffuse into the cells which have lost their membrane integrity. 
Protocol: 
1. The cells were washed with PBS (37° C). 
2. The cells were rinsed with 2 ml passage EDTA (37° C) and placed for 2 min in the 
incubator (37° C, 5% CO2). 
3. 5 ml of medium was added (37° C). 
4. The cells were scraped off the cell culture plate and transferred into a 15 ml tube. 
5. The cells were centrifuged for 10 min; (1000 xg; r.t.). 
6. After centrifugation, the pellet was thoroughly resuspended in an appropriate amount 
of PBS.  
7. Twenty µl of the cell suspension were mixed with 20 µl of trypan blue solution and 
transferred to a hemocytometer twin chamber. Living cells in the 16 squares of both 
chambers were counted, and the percentage of viable cells was determined. 
 
2.3.7. Transfection 
 
Transfection is a process in which the gene of interest is introduced to eukaryotic cells by 
biochemical or physical methods. The choice of a particular expression vector and the 
transfection methods depend on the objectives of the study. In this study, an enhanced green 
fluorescent protein (EGFP)-tagged vector was used so that transfected cells could easily be 
identified due to their green fluorescence. To deliver the nucleic acids into PC12 cells, a 
mixture of synthetic cationic lipids and neutral lipids (TransFast liposomes) was used. The 
surface of these liposomes is positively charged and attracted electrostatically to the 
negatively charged DNA. So the liposome complex neutralizes the negative charge of the 
DNA, allowing an association of the complex with the negatively charged cell membrane. 
The entry into the cell may occur by endocytosis or fusion of the plasma membrane. The 
neutral lipids disrupt endosomes and the DNA is set free into the cytoplasm. The exact 
mechanism by which the DNA enters the nucleus is still unclear. 
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In this study, stable cell clones were established. PC12 cells were plated in 6-well plates and 
cultivated until they were 90% confluent. Plasmid DNA (3.75 µg) was dissolved in 988.75 µl 
of medium (without antibiotics and serum) in a 1.5 ml tube. Subsequently, 11.25 µl of 
TransFast Reagent (suspended at least 24 h before transfection) was added and the mixture 
was vortexed briefly. The DNA/TransFast reagent mixture was incubated at r.t. for 10–15 
min. After removing the growth medium from the cells, the transfection mixture (1 ml) was 
added to each well and the plates were returned to the incubator for 1-4 h. Subsequently, 1 ml 
of medium (without antibiotics, but supplemented with 10% horse serum and 5% FCS) was 
added to each well. After 24 h, the transfection medium was replaced by growth medium and 
after another 24 h, the antibiotic G 418 (500 µg/ml) was added to select the transfected cells. 
The selection of cell clones that stably expressed the desired protein usually took 4–6 weeks. 
Several clones were tested for expression of the respective plasmid and the clones expressing 
the highest amounts of the recombinant protein were used for experiments. 
 
For activation, JNKs are phosphorylated on Thr183 and Tyr185 in the conserved Thr-X-Tyr 
MAPK activation motif. In this study both phosphorylation sites of JNK1 and JNK2 were 
mutated to inhibit phosphorylation and thereby activation of recombinant protein. So, PC12 
cells were transfected with these mutated JNK1 and JNK2 (dominant-negative JNK1 and 
JNK2). PC12 cells were also transfected with JNK3-EGFP to characterize the functional 
potential of JNK3 in 6-OHDA-induced toxicity. 
 
2.4. Denaturing protein extraction and protein quantification 
2.4.1. Harvest of cells 
1. The medium of the cells was discarded and the cells were washed with PBS. 
2. PC12 cells were rinsed again with 800 µl PBS and scraped off the plates. 
3. The cell suspension was transferred into a 1.5 ml tube and centrifuged. 
4. The supernatant was removed and the pellets were used for protein extraction. 
 
2.4.2. Denaturing extraction of whole cell proteins 
 
Denaturing lysis buffer (DLB-buffer) 
Tris     10 mM 
SDS     1% 
Phosphatase inhibitor Cocktail II 1% 
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Denatured protein extracts were prepared using a Tris-buffered sodium dodecyl sulphate 
(SDS) lysis buffer (denaturing lysis buffer). 
1. The cell pellet in a 1.5 ml tube (see 2.4.1) was resuspended in 50–300 µl of lysis 
buffer (depending on the size of the pellet).  
2. The cell solution was incubated for 5 min at 95° C in a heating block.  
3. The samples were sonicated twice for 5 s to disrupt the cells by cresting vibrations 
which cause mechanical shearing of the cell wall.  
4. Insoluble material was removed by centrifugation (15 min; 13,000 ×g; 4° C).  
5. The supernatant was transferred into a new 1.5 ml tube and stored at -80° C. 
 
2.4.3. Denaturing extraction of nuclear proteins 
 
Lysis buffer without Nonidet    Lysis buffer with Nonidet 
HEPES  10 mM   HEPES  10 mM 
KCl   10 mM   KCl   10 mM 
MgCl2   1.5 mM   MgCl2   1.5 mM 
       Nonidet  0.1% v/v 
 
To analyse nuclear proteins or the translocation of cytoplasmic proteins to the nucleus, 
cytoplasmic and nuclear proteins were extracted separately.  
1. PC12 cells were harvested (see 2.4.1.) and washed in lysis buffer without Nonidet. 
2. The cell pellets were resuspended in lysis buffer supplemented with Nonidet 
depending on the size of the pellet (80-250 µl) and placed on ice for 10 min.  
3. The cell solution was centrifuged for 5 min (11,700 ×g; 4° C).  
4. The supernatants, containing the cytoplasmic proteins, were transferred into a 1.5 ml 
tube. And 10% SDS solution was added to a final concentration of 1% SDS.  
5. Pellets were resuspended in denaturing lysis buffer to extract nuclear proteins (see 
2.4.2.).  
6. Cytoplasmic and nuclear extracts were boiled for 5 min at 95° C. 
7. Nuclear extracts were sonicated twice for 5 s as described (see 2.4.2.) and centrifuged 
(15 min; 13,000 xg; 4° C). 
8. Cytoplasmic and nuclear extracts were stored at -80° C. 
 
 
Materials and methods 
 26
2.4.4. Preparation of mitochondrial extracts 
 
Sucrose buffer 
HEPES   20 mM  DTT    1 mM 
KCl    10 mM  EGTA    1 mM 
MgCl2    1.5 mM   Sucrose   250 mM 
PMSF    0.1 mM   EDTA    1 mM 
Complete protease inhibitor 
 
For preparation of mitochondrial extracts, all steps were conducted at 4° C. 
1. Cells plated on 20 cm cell culture plates were washed twice with PBS and harvested. 
2. Cells were centrifuged for 6 min (1000 xg; 4° C). 
3. The pellets were resuspended in 4 ml of PBS and the living cells were counted with 
trypan blue (see 2.3.6.). 
4. Cells were centrifuged again; the pellets were resuspended in sucrose buffer (for 5x106 
cells 100 µl sucrose buffer) and transferred into 1.5 ml tubes. The cell solution was 
stored for 1 h on ice. 
5. After 1 h the cells were lysed by aspiration through a 27 gauge syringe (25-30 times).  
6. The lysates were centrifuged for 5 min (750 xg; 4° C). 
7. The supernatants were collected into a sterile 1.5 ml tube and centrifuged for 15 min 
(10,000 xg; 4°C). 
9. The supernatants containing the cytoplasmic proteins were transferred into a sterile 1.5 
ml tube and SDS from a 10% stock solution was added to a final concentration of 1% 
SDS. 
10. The pellets containing mitochondrial extracts were washed twice in sucrose buffer and 
lysed in DLB-Buffer (see 2.4.2). 
11. Cytoplasmic and mitochondrial extracts were boiled for 5 min at 95° C. 
12. Mitochondrial extracts were sonicated twice for 5 s as described (see 2.4.2.) and 
centrifuged (15 min; 13,000 xg; 4° C) to remove insoluble materials. 
13. Cytoplasmic and mitochondrial extracts were stored at -80° C. 
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2.4.5. Determination of protein concentrations 
 
Protein concentrations were determined using Dye Reagent, a variant of Bradford’s 
colorimetric assay. To prepare working solution, the Dye Reagent stock solution was diluted 
1:5 with DDW. 
 
To determine protein concentrations, bovine serum albumin BSA was used as protein 
standard. Serial dilution of a 1.2 mg/ml BSA stock solution in autoclaved DDW (0.1 to 0.6 
mg/ml) was produced. Samples were diluted 1:30 or 1:50 in autoclaved DDW. Twenty µl of 
sample, standard and DDW (as blank) were pipetted into the disposable plastic cuvettes. One 
ml of the working solution described above was added to each cuvette. All cuvettes were 
vortexed to start the reaction and incubated at r.t. for 10 min. The absorbance at 595 nm (A595) 
was measured using a spectrophotometer. The concentration of proteins was calculated as: 
 
  [absorbance of sample] x [concentration of standard] 
______________________________________________   x dilution factor 
  [absorbance of standard] 
 
 
2.5. Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
 (SDS-PAGE) and Western blot 
 
2.5.1. SDS-PAGE 
 
Resolving Buffer    Stacking Buffer 
Tris, pH 8.8  1.5 M   Tris, pH 6.8  0.5 M 
SDS   0.4%   SDS   0.4% 
Store at 4° C      Store at 4° C 
 
Acrylamide/bis-acrylamide solution  Electrophorese Buffer (10x) 
Acrylamide  30%   Tris, pH 8.3  0.25 M 
Bis-acrylamide 0.8%   Glycine  1.92 M 
Stored at 4° C in the dark   SDS   1%  
      Stored at r.t.  
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Sample Buffer (5x) 
Tris, pH 6.8  312.5 mM 
SDS   10% 
ß-Mercaptoethanol 10% 
Glycerol  50% 
Stored at 4° C. 
 
Sodium dodecyl sulphate- polyacrylamide gel electrophoresis (SDS-PAGE) is a low-cost, 
reproducible and rapid method for quantifying, comparing and characterizing proteins. This 
method separates proteins based on their molecular weights. SDS binds along the polypeptide 
chain and the length of the reduced SDS-protein complex is proportional to its molecular 
weight. 
 
Polyacrylamide gels were prepared by co-polymerization of acrylamide monomers with the 
cross-linker bis-acrylamide. The reaction was catalyzed by ammonium persulphate (APS) and 
initiated by N,N,N’,N’-tetramethylethylenediamine (TEMED). For better resolution, a short 
stacking gel was set on top of the main resolving gel. Differences in composition between 
these two gels resulted in concentration of the protein samples into narrow bands in the 
stacking gel and separation of the bands according to their size in the resolving gel. Table 2.3 
and 2.4 provides the composition of stacking and resolving gels. For preparation of the 
resolving gel different percentages of acrylamide were used, depending on the molecular 
weight of protein to be analyzed. A 15% resolving gel was used to detect cytochrome c, 
caspase-8, cleaved caspase-3 and caspase-3 proteins, whereas a 10% resolving gel was used 
for PARP-1 protein. The remaining proteins were analyzed in a 12% resolving gel. (Table 
2.5.). 
Table 2.3. Composition of separating gels for SDS-PAGE 
Target protein size < 30 kDa 30-60 kDa 60–100 kDa 
Components 15% gel 12% gel 10% gel 
Acrylamide 6.7 ml 4 ml 3.3 ml 
4 × resolving buffer 2.3 ml 2.5 ml 2.5 ml 
Autoclaved DDW 2.3 ml 3.4 ml 4.1 ml 
TEMED 10 µl 10 µl 10 µl 
10% APS 100 µl 100 µl 100 µl 
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Table 2.4. Composition of the 3% stacking gel for SDS-PAGE 
Component Quantity 
Acrylamide 0.6 ml 
4 × stacking buffer 1.5 ml 
Autoclaved DDW 3.9 ml 
TEMED 6 µl 
10% APS 60 µl 
 
Preparation of polyacrylamide gels 
 
Glass plates from a MiniProtean II Vertical PAGE chamber were cleaned with 70% ethanol, 
clamped together and placed in a vertical position on the bench top. A mark on the glass plate 
1 cm below the teeth of the comb was placed to determine the level of resolving gel which 
had to be poured. Resolving gel monomer solution combining all reagents containing TEMED 
and APS was prepared. The solution was pipetted between the gel plates to the mark. The 
solution was carefully introduced to minimize possibility of air bubbles trapped within the 
gel. When the appropriate resolving gel solution was added, the gel was over-layed with 
DDW to keep the gel surface flat and allowed to polymerize for 10-30 min at r.t. After 
polymerization, a distinct interface appeared between the separating gel and DDW which has 
to be removed. 
 
Subsequently, the stacking gel (Table 2.4) was prepared and pipetted on top of the 
polymerized resolving gel until the solution reached top of front plate. Immediately, a 15-well 
comb was inserted into the gel plates. It is important to be sure that bubbles were not trapped 
on the ends of teeth. The stacking gel was allowed to polymerize within 30 min at r.t. 
 
After the stacking gel had polymerized the comb was removed carefully and the gel plates 
were placed into electrophoresis chamber. The chamber was filled with 1x electrophoresis 
buffer and the wells were cleaned from residual gel particles. 
 
Preparation of protein samples 
 
Protein samples, used for Western blot were diluted with autoclaved DDW in order to obtain 
20 µg of total protein in a volume of 8 µl. Two µl of 5 × SDS sample buffer were added, and 
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the samples were heated to 95° C for 5 min and loaded onto the gel. To estimate the 
molecular weights of bands detected by Western blotting, broad range prestained protein 
marker was used. 
 
Electrophoresis 
 
The samples and the protein marker were carefully loaded into the cleaned wells and run 
through the stacking and resolving gels at a constant current of 30 mA. Usually, gels were run 
for 30 min after the tracking dye had passed the end of the gel. Finally, gels were removed 
from the gel plates, the stacking gel was discarded, and the resolving gel was used for 
Western blotting (see 2.5.2). 
 
2.5.2. Western blot 
 
TBS (10x)    TTBS    Blocking Solution  
Tris  200 mM  TBS  1x  4% non fat dry milk 
NaCl  1.37 mM  Tween-20 1 ml/ l  in TTBS 
Store at 4° C    Store at 4° C   Store at 4° C 
 
Anode Buffer I   Anode Buffer II 
Tris  30 mM  Tris  300 mM 
Methanol 20%   Methanol 20%  
 
Cathode Buffer 
Tris   25 mM 
Methanol  20% 
6-aminocaproic acid 40 mM 
Store at r.t. 
 
In Western blotting experiments proteins are transferred from a SDS-PAGE gel to a synthetic 
membrane and then the proteins are detected. Once the proteins have been transferred from 
the polyacrylamide gel to the synthetic membrane, specific proteins were detected by specific 
antibodies. Prior to addition of antibodies, the membrane is coated with blocking solution e.g. 
non-fat milk or a BSA solution. Blocking the membrane is very important so that antibodies 
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do not bind non-specifically to the membrane. The primary IgG (e.g. produced in mice) 
antibody recognizes the protein of interest while the secondary antibody recognizes the Fc 
portion of the first antibody. This secondary antibody is coupled to an enzyme, e.g. a 
horseradish peroxidase (HRP), which converts a chemiluminescence substrate. 
 
Blotting 
 
After the proteins were separated by SDS-PAGE, they were transferred to a polyvinylidene 
difluoride (PVDF) membrane by semi-dry blotting using an electroblotter. Three different 
transfer buffers were used (anode buffer I and II, cathode buffer). The PVDF membrane 
which was cut to the size of gel (9 x 6 cm) was activated in 100% methanol for 3 min. 
Subsequently, the membrane was rinsed in DDW for 2 min and equilibrated in anode buffer I 
until use. For each gel, 15 pieces of blotting paper were cut to the size of the gel (9 × 6 cm). 
Six pieces of them were pre-soaked in anode buffer II and placed on a glass plate. Three 
pieces of blotting paper were pre-soaked in anode buffer I and placed over the anode buffer 
II-soaked filter paper. The equilibrated membrane was then placed over the filter paper and 
the gel was placed in close contact with membrane after pre-soaked in cathode buffer. The 
‘sandwich’ was completed by stacking remaining 6 pieces of filter paper pre-soaked in 
cathode buffer. Finally, the blotting ‘sandwich’ was turned around and placed into the semi-
dry transfer unit in which the bottom is the cathode. 
 
Proteins were transferred to the PVDF membrane using a constant current of 0.8 mA/cm2 for 
1 h (protein size 30–80 kDa) or 1.5 h (> 80 kDa). After transferring the protein to the 
membrane, the membrane was washed for 20 min in 1 x TTBS buffer and blocked with 
blocking solution for 60 min. Subsequently, the membrane was incubated with the first 
antibody at 4° C overnight. 
 
On the next day, the primary antibody solution was discarded and the unbound antibody was 
removed by washing the membranes once for 15 min and twice for 5 min each with TTBS. 
Usually the membrane was incubated with a dilution of 1:4000 goat-anti-rabbit secondary 
antibody or with a dilution of 1:3000 goat-anti-mouse secondary antibody for 30 min at r.t. 
After discarding the secondary antibody solution, the membrane was washed once for 15 min 
and three times for 5 min each with TTBS. 
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Table 2.5. Primary and secondary antibodies for Western blots 
Antibody Dilution and Buffer Second 
antibody 
Manufacturer 
Caspase-3 1:1000 in blocking solution α-rabbit Santa Cruz 
Caspase-8 1:500 in blocking solution α-rabbit Santa Cruz 
Cleaved caspase-3 1:1000 in blocking solution α-rabbit CST 
Cytochrome c 1:5000 in blocking solution α-mouse BD 
Grp-75 1:5000 in TTBS α-mouse Stressgen 
JNK1 1:1000 in TTBS α-mouse Pharmingen 
JNK2 1:1000 in blocking solution α-mouse Santa Cruz 
JNK3 1:1000 in TTBS α-rabbit Alexis 
JIP-1 1:1000 in blocking solution α-rabbit Santa Cruz 
MKK4  1:500 in TTBS α-rabbit Santa Cruz 
MKK7  1:1000 in blocking solution α-rabbit Santa Cruz 
MKP 7 1:2000 in TTBS α-rabbit generous gift from 
Dr. A. Whitmarsh 
phospho-c-Jun 1:1000 in TTBS α-rabbit CST 
phospho-JNK 1:2500 in blocking solution α-rabbit Promega 
phospho-MKK4 1:500 in TTBS α-rabbit Santa Cruz 
PARP-1 1:2000 in TTBS α-mouse Alexis 
total JNK 1:1000 in TTBS α-rabbit CST 
ß-Actin 1:5000 in TTBS α-mouse Sigma 
 
ECL-Reaction 
 
After the last washing step, the membrane was placed with the protein side up on a glass 
plate. For a 6 × 9 cm (standard sized) membrane, 1 ml of ECL Plus HRP substrate was 
prepared immediately prior to use by mixing 0.975 ml of ECL Plus Reagent A with 25 µl of 
ECL Plus Reagent B. The membrane was carefully covered with the HRP substrate solution 
and incubated for 3 min. Subsequently, all the HRP substrate was allowed to drip off the 
membrane and the membrane was placed inside the plastic pocket of a film cassette. The 
chemiluminescence on the membranes was detected by exposing the membranes to Hyperfilm 
ECL films in a darkroom. Films were developed and fixed by a film processor. 
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2.5.3. Stripping of Western blot membranes 
 
Stripping solution 
Tris   62.5 mM 
SDS   2% 
ß-Mercaptoethanol 100 mM 
Store at 4° C. 
 
After Western blotting and detection of the protein, the membrane can be used to detect 
another protein. For stripping, the membrane was incubated for 30 min at 50° C and 25 rpm in 
an incubator. After stripping, the membrane was washed twice for 10 min each with TTBS 
and blocked with blocking solution for 1h. Subsequently, the membrane was incubated with 
primary antibody. 
 
2.5.4. Ponceau S staining of Western blot membranes 
 
Ponceau S is the only staining method which is completely compatible with all procedures of 
immunological probing, because the stain is transient and can be washed away so that it does 
not interfere with subsequent detection of antigens. After the ECL reaction, membranes were 
washed twice with TTBS and then stained with Ponceau S for 20 min. The staining solution 
was re-used several times. Stained membranes were washed twice with DDW for 5 min each 
before air-drying. 
 
2.6. Isolation of RNA 
 
2.6.1 RNA extraction 
 
During RNA extraction it is very important not to have any contamination with RNAse. So all 
of the equipments used were autoclaved and the working place was cleaned with 70% ethanol. 
For the isolation of total RNA extraction NucleoSpin® RNA II isolation kit was used. The 
cells were harvested as described in section 2.4.1. The pellet was re-suspended in lysis buffer 
(350 µl RA1 buffer with 3.5 µl ß-mercaptoethanol per sample). The cell solution was applied 
to a NucleoSpin® Filter unit (violet) and centrifuged for 1 min (11,000 xg; r.t.). The filter unit 
was discarded, 350 µl ethanol (70%) was added to the homogenized lysate and mixed. The 
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lysate was loaded to the NucleoSpin® RNA II column and centrifuged for 30 s (8,000 xg; 
r.t.). The column was placed in a new collection tube, 350 µl MDB (Membrane Desalting 
Buffer) was added and centrifuged for 1 min (11,000 xg; r.t.) to dry the membrane. 
Subsequently, 95 µl DNAse reaction mixture (10 µl DNAse I + 90 µl DNAse reaction buffer) 
was added directly onto the center of the membrane and incubated at r.t. for 15 min. To 
inactivate DNAse, 200 µl RA2 buffer was added to each column and centrifuged for 30 s 
(8,000xg; r.t.). After washing the pellet twice with RA3 buffer, the column was placed into a 
nuclease-free 1.5 ml tube and RNA was eluted in 60 µl RNAse-free water. A 5 µl aliquot of 
the RNA solution was removed for quantification and quality validation. The remaining RNA 
was stored at -80° C. 
 
2.6.2. RNA quantification and quality control 
 
RNA concentration was determined by measuring the absorbance at 260 nm (A260) in a 
spectrophotometer. RNA samples were diluted 1:200 in RNAse-free water and pipetted into 
quartz cuvettes. Absorbance of RNAse-free water was measured as blank. An absorbance of 1 
unit at 260 nm corresponds to 40 µg/ml of RNA in water. RNA concentration could be 
determined as; 
CRNA  = A260 x dilution factor x 40 
 
To detect protein contaminants, the absorbance at 280 nm was also measured. The ratio of the 
absorbance at 260 nm and 280 nm (A260/A280) gives us the purity of RNA. A ratio of 1.6–2.0 
indicates pure RNA (in water). 
 
2.7. Polymerase chain reaction (PCR) 
 
2.7.1. Reverse transcription polymerase chain reaction (RT-PCR) 
 
Reverse transcription polymerase chain reaction (RT-PCR) is a method which combines 
complementary DNA (cDNA) synthesis from RNA templates with using a RNA-dependent 
DNA polymerase (the reverse transcriptase, RT). The RT can start from oligo (dT) primers 
binding to the polyadenylated tail of the mRNAs. In this study reverse transcription is carried 
out with the SuperScript First-Strand Synthesis System for RT-PCR. 
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For the reverse transcription, 5 µg of RNA were diluted in a volume of 11 µl DEPC-DDW. 
One µl of the oligo(dT) solution was added to each sample and incubated in a thermocycler at 
70° C for 10 min to denaturate the samples. Subsequently the temperature was decreased to 4° 
C and during this time the RT master mix was prepared on ice. 
 
Table 2.6. Composition of RT the master mix 
Component Quantity  
10 x PCR Buffer 2 µl 
MgCl2 (25 mM) 2 µl 
dNTP mix (10 mM) 1 µl 
DTT (0.1 mM) 2 µl 
 
Seven µl of the RT master mix was added to the each sample and incubated at 42° C for 5 min 
for annealing of the primer. Subsequently, 1 µl SuperScript II RT was added to each sample 
and incubated at 42° C for 50 min and followed by 70° C for 15 min to denaturate RNA-
cDNA hybrids. To stop the reaction 1 µl RNAse H was added to each sample and incubated at 
37° C for 20 min. cDNA samples were used immediately for PCR or stored at -20° C. 
 
2.7.2. PCR 
 
The purpose of a PCR (polymerized chain reaction) is to make a huge number of copies of a 
gene. There are three basic steps in PCR. First, the target genetic material must be denatured, 
i.e. the strands of its helix must be unwound and separated by heating to 90-96° C. The 
second step is hybridization or annealing, in which the primers bind to their complementary 
bases on the single-stranded DNA. Annealing temperature chosen for a PCR depends directly 
on length and composition of the primers and calculated using the following formula: 
 
TM = 4 x (number of G + C) + 2 x (number of A + T). 
 
The third step is DNA synthesis by a polymerase. Starting from the primer, the polymerase 
can read a template strand and match it with complementary nucleotides very quickly. This 
results in two new helixes in place of the first, each composed of one of the original strands 
plus its newly assembled complementary strand. Repeating these cycles results in generating 
millions of copies of DNA strands. 
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The cDNA produced in the RT reaction was amplified in a total volume of 50 µl in a 
thermocycler. Two µl of cDNA sample were pipetted into single PCR tubes and placed on 
ice. The PCR master mix was prepared on ice and 48 µl of master mix was added to each 
sample. 
 
Table 2.7. The master mix for PCR 
Component Quantity (for 48 µl per sample) 
10 x PCR Buffer 5 µl 
MgCl2 (50 mM) 2 µl 
dNTP mix (10 mM) 1 µl 
Forward primer (10 µM) 1 µl 
Reverse primer (10 µM) 1 µl 
Taq DNA polymerase 0.25 µl 
Autoclaved DDW 37.5 µl 
 
After addition of the PCR master mix, samples were placed in a thermocycler and the PCR 
program was started. 
 
PCR-Program 
1. 94°C, 5 min 
2. 94°C, 1 min 
3. 53°C, 1 min (annealing temperature)  25x 
4. 72°C, 30 s 
5. 72°C, 10 min 
6. 4°C,  ∞ 
 
In this study primers for Bim and for the house-keeping-gen H2.Az were used. All primers 
were designed using the software Primer 3 Software Distribution (Whitehead 
Institute/Howard Hughes Medical Institute; Boston, MA, USA). The specificity of the primer 
pairs was verified by comparative alignment using the BLAST database 
(http://www.ncbi.nlm.nih.gov/BLAST/) at the National Center for Biotechnology Information 
(NCBI; Bethesda, MD, USA).  
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Table 2.8. Primer pairs and reaction conditions for PCR amplications 
Gene Primers Product 
(bp) 
Annealing 
temp. (°C) 
Number 
of cycles 
 
Bim 
fw: CAACACAAACCCCAAGTCCT 
rv: TCTTCCGCCTCTCGGTAAT 
 
   182 
 
    55 
 
   25 
 
H2A.z 
fw: CGTATTCATCGACACCTGAAA  
rv: CTGTTGTCCTTTCTTCCCAAT 
 
  282 
 
    55 
 
   25 
 
After the PCR, the products were aliquoted and stored at –20° C. An aliquot of the sample 
was used to visualize by agarose gel electrophoresis. 
 
2.7.3. Detection and analysis of the reaction product 
 
10x TBE-Buffer (Tris-boric acid-EDTA buffer)  10x Loading Buffer 
Tris  9 M      Bromophenol blue 0.25% 
Boric acid 9 M      Glycerol  30% 
EDTA  0.2 M      
Store at r.t.       Store at 4° C. 
 
Agarose 
Agarose (dissolved in TBE buffer) x % 
Ethidium bromide   5 µg/ml 
Prepared freshly. 
 
The PCR product should be a fragment or fragments of defined DNA lengths. The simplest 
way to check for the presence of these fragments is to load a sample taken from the reaction 
product, along with appropriate molecular-weight markers onto an agarose gel. One % or 
1.5% agarose gels were prepared with 1x Tris-buffer boric acid-EDTA. The 1x TBE buffer 
was set up by diluting 10x TBE buffer with DDW. The required amount of agarose was 
dissolved in 1x TBE buffer by heating in a microwave oven. 5 µl/100 ml of a 10 mg/ml 
ethidium bromide stock solution was added to warm agarose solution and mixed well. For 
agarose gel electrophorese a horizontal gel system was used. The agarose solution with 
ethidium bromide was pipetted to this gel system and allowed to polymerize for 20-30 min. 
Materials and methods 
 38
When the gel had polymerized, it was transferred to an electrophorese chamber filled with 1x 
TBE buffer. Twenty µl of DNA sample were mixed with 5 µl 10 x Loading buffer in 1.5 ml 
tubes. At the same time 1 µl DNA-Ladder was mixed with 5 µl 10 x Loading buffer and with 
19 µl TBE buffer, resulting in a total volume of 25 µl. The DNA-Ladder and the samples 
were loaded into wells and the gel was run at 80 mV for ca. 60 min. Bands were visualized 
with 312 nm UV light. 
 
2.8. Culture, staining and stimulation of primary cells 
 
2.8.1 Solutions for primary cultures 
Hanks Solution      Dissection Solution 
Pulver media   w/o Mg2+ and Ca2+  Hanks solution   
NaHCO3  35 mg/ml   Albumin  3 mg/ml 
HEPES  10 mM   MgSO4  1.4 mg/ml 
D-Glucose  6 mg/ml 
Gentamycin  5 µg/ml 
 
Digestion Solution     Culture Media  
NaCl   8 mg/ml   MEM 
KCl   0.37 mg/ml   D-glucose  5mg/ml 
Na2HPO4  0.99 mg/ml   Transferrin  0.1 mg/ml  
HEPES  5.95 mg/ml   Insulin   25 µg/ml 
NaHCO3  0.35 mg/ml    Glutamax  2 mM 
       Gentamycin  5 µg/ml 
 
1st day culture media     3rd day culture media 
Culture media      Culture media 
FCS / HS  10%    FCS / HS  5% 
B 27 supplement 2% 
AraC   5 µM  
All of the solutions are at pH 7.4 and stored at 4° C 
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2.8.2. Coating of the plates 
 
For providing cell attachment and growth, 4-well plates and culture dishes (35 mm) have to 
be coated. Cover glasses or plastic cover slips were placed in 4-well plates in the LFU. Plastic 
culture dishes and 4-well plates were coated with poly-l-Lysine, dissolved in ultrapure water 
(100 µg/ml). To coat the culture dishes or 4-well plates, the bottom of the slides was covered 
with a thin layer of poly-l-Lysine, and placed in the incubator overnight. The next day, slides 
were washed two times with DDW. Subsequently, 1st day culture medium was added to the 
plates and placed in the incubator until use. Cover glasses used in this study were not sterile. 
So they were autoclaved before use and stored under sterile conditions. 
 
2.8.3. Culturing of primary rat neurons 
 
Hippocampal or cortical cultures were obtained from the newborn rats (up to 24 h postnatal). 
All the culturing procedure was performed on ice. Rat puppies were decapitated and the 
brains were dissected under sterile conditions. Brains were transferred into petri-dishes which 
contain ice-cold dissection solution. Cortex and hippocampus were dissected and cleaned 
from blood vessels and meninges. Subsequently, they were transferred into different petri-
dishes and cut into 1 mm3 pieces and finally transferred into 15 ml tubes. After washing 4 
times with 3 ml dissection solution and treating with 5 ml Hanks solution, hippocampal and 
cortical slices were warmed for 1 min in digestion solution, mixed with trypsin (3.3 mg/ml), 
DNAse (0.83 mg/ml), and treated with the same solution for 5 min at r.t. The hippocampal 
and cortical slices were then incubated in dissection solution with 0.6 mg/ml trypsin inhibitor 
to inhibit trypsin activity for 5 and 3 min, respectively, and finally with fetal calf serum (200 
µl/ml in dissection solution) for 10 min. Hippocampal and cortical slices were washed 4 times 
with dissection solution and homogenized in dissection solution, mixed with 0.4 mg/ml 
DNAse, with three different diameters of fire polished Pasteur pipettes. Five ml of dissection 
solution were added and the cells were centrifuged (15 min; 800 xg; 4° C). To determine the 
number of surviving cells in cell suspension, cells were counted with trypan blue (see 2.2.5.). 
Subsequently, cells were plated on 4 well plates or 35 mm plastic culture dishes containing 1st 
day culture media (Culture Media, 10% FCS). After two days half of the culture media was 
replaced with 3rd day media and every 2nd –3rd day half of the media was replaced with fresh 
culture medium. 
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This culturing procedure results in a mixed neuronal culture containing 70-80% neurons. The 
remaining cells were identified as astrocytes. 
 
2.8.4. Culturing of primary murine neurons 
 
Cortical cultures from newborn mice (up to 24 h) were obtained as described above (see 
2.8.3). However, instead of 10% FCS, 10% horse serum was used for culturing and feeding of 
the primary murine neurons. 
 
2.8.5. Incubation with inhibitors and other substances 
 
Five days old hippocampal cultures were treated with 250 µM glutamate freshly made from a 
5 mM stock solution, for 4 or 24 h in the culture medium without serum and B27 supplement. 
Five days old cortical cells were treated with 25 µM, 50 µM, and 100 µM 6-OHDA freshly 
made from 100 mM stock solution in ascorbic acid solution to prevent oxidation. The JNK-
inhibitor SP600125 (2 µM) was given to the both cultures 30 min before the addition of 
glutamate or 6-OHDA. 
 
2.9. Immunocytochemistry 
 
Immunocytochemistry bases on the use of a primary antibody directed against the cellular 
target(s) and a secondary antibody which is directed against the primary antibody and labelled 
with an enzyme. The most commonly used enzymes are peroxidase and alkaline phosphatase. 
Peroxidase activity is most frequently detected using 3,3’-Diaminobenzidine (DAB) as the 
electron acceptor with hydrogen peroxide serving as the substrate. The reaction product is 
observed as a brown precipitate at the site of the enzyme activity. To enhance the signal, the 
secondary antibody is biotinylated and in consequence bound by avidin coupled to a complex 
containing the enzyme (avidin-biotin-complex coupled with a peroxidase for the substrate 
reaction, i.e. the ABC complex). The immunocytochemical procedure involves fixation, 
permeabilization, blocking sites that are prone to unspecific interactions, labelling with the 
primary and secondary antibodies, incubation with the ABC complex and finally the substrate 
reaction. 
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Staining was performed using the following protocol: 
1. The cells were incubated with pre-warmed para-formaldehyde (4% in PBS, 37° C) at 
r.t. for 30 min. 
2. The fixed cells were permeabilized with Triton X-100 (0.2% in PBS) at r.t. for 2 min. 
3. The cells were blocked in 5% normal goat serum, diluted in PBS. 
4. The cells were washed in 1% normal goat serum, diluted in PBS, two times for 3 min 
each. 
5. The cells were incubated with primary antibody (overnight at 4° C). 
6. The cells were washed in PBS, three times for 3 min each. 
7. The cells were incubated with secondary antibody for 1 h (37° C). 
8. The cells were washed in PBS, three times for 3 min each. 
9. The cells were incubated with ABC complex for 1 h. (37° C). 
 
ABC solution: Vectastain® Elite ABC Reagent (Vector). Two drops of reagent A were 
added to 5 ml of PBS. After the addition of two drops of reagent B the solution was mixed 
immediately. The solution was ready to use after 30 min. 
 
10. The cells were washed in PBS, two times for 3 min each. 
11. The cells were incubated in DAB solution until staining was optimal as determined by 
light microscopic examination (5-10 min at r.t.). 
 
DAB Reagent: 3,3`-diaminobenzidine tablet sets (Sigma). When dissolved in 5 ml DDW 
each Sigma Fast DAB tablet sets contains O9292 DAB: 0.7 mg/ml; U1380 Urea Hydrogen 
Peroxide: 0.2 mg/ml and Tris buffer 0.06 M.  
 
12.  The cells were washed in DDW two times each for 5 min. 
 
The stained cells were mountained and analyzed using a DMR microscope with a camera 
system and the software LeicaQwin. 
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2.9.1. Double staining 
 
The cells were fixed, permeabilized, incubated with the primary and the secondary antibody 
as described above. After incubation with ABC solution and DAB reagent, the cells were 
incubated with another primary antibody overnight at 4° C. After that, the cells were 
incubated with secondary antibody against the second primary antibody. After ABC 
incubation, the cells were stained with Vector® SG substrate kit which gives a blue-grey 
signal. The stained cells were analyzed as described above. 
 
Vector® SG substrate kit: Three drops of chromogen were added to 5 ml of PBS. After the 
addition of three drops of hydrogen peroxide, the solution was mixed immediately. 
 
2.9.2. Immunofluorescence staining 
 
The cells were fixed, permeabilized and incubated with the primary antibody as described 
above. The next day after removing the unbound antibody, the cells were incubated with a 
fluorescein (FITC)-conjugated secondary antibody against the primary antibody. The cells 
were mountained with an anti-fade kit and visualized under fluorescence microscope using a 
camera system and a software program. 
 
Table 2.9. Primary and secondary antibodies for immunocytochemistry and 
immunofluorescence 
First 
Antibody 
Manufacturer Second antibody for 
immunocytochemistry 
Second antibody for 
immunofluorescence 
GFAP Santa Cruz Biotinylated anti-rabbit IgG FITC-conjugated anti-rabbit IgG 
JNK1 Pharmingen Biotinylated anti-mouse IgG FITC-conjugated anti-mouse IgG 
JNK2 Santa Cruz Biotinylated anti-mouse IgG FITC-conjugated anti-mouse IgG 
MAP-2 Chemicon Biotinylated anti-mouse IgG FITC-conjugated anti-mouse IgG 
p-c-Jun CST Biotinylated anti-rabbit IgG FITC-conjugated anti-rabbit IgG 
p-JNK Promega Biotinylated anti-rabbit IgG FITC-conjugated anti-rabbit IgG 
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2.10. LDH Assay 
 
Lactate dehydrogenase (LDH) is a stable cytoplasmic enzyme that is present in all cells. An 
increase in the amount of cell death or plasma membrane damaged cells results in an increase 
of the LDH enzyme activation in the culture supernatant which directly correlates to the 
amount of formazan formed during a limited time period. Therefore, the amount of colour 
formed in the assay is proportional to the number of lysed cells. 
 
For the experiments a kit from Roche was used and the experiments were performed 
according to manufacturer’s instruction. The culture supernatant is collected in a 1.5 ml tube 
and centrifuged (2000 xg; 10 min; 15-20° C). Subsequently, a 96-well tissue culture plate was 
filled with 100 µl supernatants. To determine LDH activity in the supernatants 100 µl reaction 
mixture was added to each well and incubated 30 min at 15-25° C. During this incubation 
period the 96-well plates was protected from light. Finally, the absorbance of the samples was 
measured at 490 nm using an ELISA reader. 
 
Reaction Mixture: The reaction mixture should be prepared freshly. For 100 tests 250 µl of 
solution I was mixed with 11.25 ml of solution II before use. 
 
2.11. Staining of the cells with Hoechst Dye 
 
For evaluation of apoptotic cells Hoechst 33258 (Sigma) was used. Hoechst 33258 binds all 
DNA and stains nuclear material allowing the visualization of apoptotic nuclei. For the 
staining, untreated and stimulated cells were fixed with 4% paraformaldehyde for 30 min at 
r.t. and permeabilized with 0.2% Triton X-100 in PBS. After washing the cells in PBS three 
times, the cells were incubated with Hoechst 33258 for 15 min at r.t. (5 µg/ml in PBS). 
 
The stained cells were analyzed using a fluorescence microscope with a camera system and 
the software Analysis. 
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2.12. Statistical analysis  
 
Unless otherwise indicated, all experiments were carried out independently 3-6 times. 
Statistical analysis was performed with GraphPrism software (www.graphpad.com) using 
one-way analysis of variance with repeated measures. Means were compared using the post-
hoc Bonferroni test, and significance was defined for p ≤ 0.05. Data were expressed as mean 
± standard deviation. 
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3. Results 
 
3.1. Function of JNK isoforms following 6-hydroxydopamine-(6-OHDA-) induced 
oxidative stress  
 
The first aim of this study was to investigate the specific actions of JNK isoforms in oxidative 
stress that is connected with mitochondrial dysfunction in PC12 cells. 
 
3.1.1. 6-OHDA-induced cell death in PC12 cells 
 
To examine the 6-OHDA-induced toxicity, PC12 cells were treated with different 
concentrations of 6-OHDA for 24 h. Cell death was detected by trypan blue exclusion assays. 
Twenty-five µM, 50 µM and 100 µM 6-OHDA induced significant cell death in PC12 cells 
(Fig. 3.1). 
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Fig. 3.1. Cell death in response to 6-OHDA 
The diagram shows the survival of cells in response to 6-OHDA after 24 h. Cell death was determined 
by trypan blue exclusion assay. n = 4, +++ gives the significance compared with controls for p ≤ 
0.001. 
 
3.1.2. Activation of JNK and c-Jun 
 
6-OHDA dose-dependently induced a distinct phosphorylation of JNKs in the cytoplasm and 
the nucleus. Concomitantly, the N-terminal phosphorylation of c-Jun dose-dependently 
increased in the nucleus (Fig. 3.2 A and B). 6-OHDA induced JNK activation after 4 h in the 
cytoplasm and the nucleus. According to this time course the majority of experiments were 
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performed at the time point of maximal JNK activity, i.e. 4 h after 6-OHDA stimulation (Fig. 
3.2 A). The distribution of JNK isoforms changed depending on the concentration of 6-
OHDA. JNK1 and JNK2 did not change in the cytoplasm following 6-OHDA, while the 
amount of JNK2 increased in the nucleus between 10 µM and 50 µM 6-OHDA. JNK1 levels 
did not change in the nucleus after different concentrations of 6-OHDA (Fig. 3.2 B). Thus, the 
augmentation in total phospho-JNK in the nucleus paralleled the increase of JNK2. 
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Fig. 3.2. Phosphorylation of JNKs and c-Jun in response to 6-OHDA 
A. JNKs were dose dependently phosphorylated in the cytoplasm and the nucleus 4 h after 6-OHDA 
treatment as compared to control groups (co). B. JNKs were phosphorylated in the nucleus and the 
cytoplasm after 4 h of 6-OHDA stimulation, but only JNK2 was translocated to the nucleus in 
response to 6-OHDA. Neither the expression of JNK1 nor JNK2 displayed any changes in the 
cytoplasm. n = 4. 
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3.1.3. Protection by SP600125 and dnJNK2 
 
To investigate the role of JNKs in the 6-OHDA-induced cell death, the direct and specific 
JNK-inhibitor SP600125 was used. As analyzed in trypan blue exclusion assay, addition of 25 
µM 6-OHDA caused substantial cell death after 24 h. The pre-incubation with 1 µM or 2 µM 
SP600125 rescued 51% and 68% of the otherwise dying PC12 cells (Fig. 3.3). 
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Fig. 3.3. Protection of PC12 cells by the direct JNK-inhibitor SP600125  
Pre-incubation with 1 µM or 2 µM SP600125 (30 min) significantly protected PC12 cells from 6-
OHDA-induced cell death. n = 4. Controls = 100%. +++ (p ≤ 0.001) and ++ (p ≤ 0.01) refer to 6-
OHDA vs. controls, *** (p ≤ 0.001) indicates significant differences between 6-OHDA vs. SP600125 
and 6-OHDA. 
 
The inhibition of JNKs, however, does not provide a permanent protection. Forty-seven and 
seventy-four hours after 25 µM 6-OHDA (without change of the medium), the survival rates 
did not differ significantly between the SP600125-treated cells and controls (Fig. 3.4 B). This 
fading protection of JNK inhibition suggests a switch from an early JNK-dependent to a late 
JNK-independent pathway to cell death. However, SP600125 did not protect against 50 µM 
6-OHDA-induced cell death at any time point (Fig. 3.4 C). The time window for SP600125- 
mediated protection is smaller than 4 h, since JNK inhibition was still effective when applied 
2 h but not 4 h after 6-OHDA (Fig. 3.4 A). Thus, the protective time window of SP600125 
can be correlated with the onset of JNK and c-Jun activation beginning between 2 h and 4 h 
post-stimulus. 
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Fig. 3.4. Protection of PC12 cells from 6-OHDA-induced death is time dependent  
A. Survival of PC12 cells (Trypan blue exclusion assay) 24 h following 25 µM 6-OHDA and 2 µM 
SP600125 either 30 min prior or 2 h and 4 h after the onset of 6-OHDA treatment. SP600125 
conferred its protection when applied 30 min prior or up to 2 h after stimulation with 6-OHDA. B. 
SP600125 was not protective after 48 h and 72 h. C. SP600125 had no protective effects against 50 
µM 6-OHDA at any time point. 
n = 4. Controls = 100%. +++ (p ≤ 0.001) and ++ (p ≤ 0.01) refer to 6-OHDA vs. controls, *** (p ≤ 
0.001) indicates significant differences between 6-OHDA vs. SP600125 and 6-OHDA. 
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The translocation of JNK2 into the nucleus, which paralleled the increase of JNK activity, 
raised the question if JNK2 is responsible for 6-OHDA-mediated death rather than the more 
´physiological` or even ´protective` JNK1 [60, 87]. For this purpose, PC12 cells were stably 
transfected with EGFP-tagged dnJNK1 (dominant-negative) and dnJNK2 (see 2.3.7). 
DnJNK2, but not dnJNK1, protected PC12 cells from cell death induced by 25 µM 6-OHDA 
(Fig. 3.5 A). Similar to SP600125, dnJNK2 was not protective after 48 h and 72 h (data not 
shown). It did not protect against 50 µM 6-OHDA-induced cell death (Fig. 3.5 A). 
Interestingly, pre-incubation of dnJNK2 with SP600125 did not protect cells from 25 µM 6-
OHDA-induced cell death. Moreover, with SP600125 treatment, the protection of dnJNK2 
was lost (Fig. 3.5 B). 
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Fig. 3.5. Protection of PC12 cells from 6-OHDA-induced death is dose dependent 
A.Trypan blue exclusion assays 24 h after stimulation showed that JNK-inhibition – either by pre-
treatment with 2 µM SP600125 (30 min) or transfection with dnJNK2 – significantly reduced cell 
death in response to 25 µM 6-OHDA whereas dnJNK1 had no protective effects. Cell death triggered 
by 50 µM 6-OHDA, however, could not be prevented by JNK-inhibition. B. Pre-incubation of 
dnJNK2 with SP600125 did not protect the cells from death induced by 25 µM 6-OHDA. 
n = 4. +++ (p ≤ 0.001) indicates significant differences between 6-OHDA vs. JNK inhibition. co, 
unstimulated. 
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Fig. 3.6. Effects of dnJNK2 on the activation and localization of JNKs 
 A. After stimulation with 25 µM and 50 µM 6-OHDA JNKs are activated in nucleus and cytoplasm. 
Only transfection with dnJNK2 reduced JNK activity. B. Twenty-five µM 6-OHDA increased the 
translocation of JNK2 into the nucleus in vector controls. Translocation of endogenous JNK2 into the 
nucleus was inhibited by transfection of dnJNK2. C. Pre-incubation of PC12 cells with SP600125 
inhibited the translocation of JNK2, but not JNK1 into the nucleus.  
n = 4. co, unstimulated. 
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Transfection of dnJNK2 interfered with the activation of JNKs. Importantly, dnJNK2 reduced 
the pool of phosphorylated total JNK in the nucleus after stimulation with 6-OHDA to a much 
higher extent than in the cytoplasm, while dnJNK1 had not such effect (Fig 3.6 A). In contrast 
to wild type cells, transfection with dnJNK2 strongly reduced the 6-OHDA-induced 
translocation of endogenous JNK2 to the nucleus (Fig. 3.6 B). The construct itself was almost 
completely excluded from the nucleus since it was barely detectable in nuclear preparations, 
but clearly visible in the cytoplasm (Fig.3.6 B). Similar to dnJNK2, SP600125 inhibited the 
translocation of JNK2, but not JNK1 to the nucleus (Fig. 3.6 C). 
 
3.1.4. Translocation of JNK2, but not JNK1 to the mitochondria 
 
Translocation of JNK2 into the nucleus after 6-OHDA treatment raised the question whether 
JNK2 also translocates to the mitochondria, the central target organelles of 6-OHDA-
mediated pathology. One and 2 h after 6-OHDA treatment, the amount of JNK2 present at the 
mitochondria increased and reached its maximal level at 4 h (Fig. 3.7 A). Dominant-negative 
JNK2 could not be detected at the mitochondria, as it was seen in the nucleus. Moreover, 
dnJNK2 did not interfere with the increase of endogenous JNK2 at the mitochondria 
following 25 µM 6-OHDA (Fig. 3.7 A) or with the mitochondrial pool of JNK1 (Fig. 3.7 B). 
 
In contrast to JNK2, a substantial amount of JNK1 was present at the mitochondria of 
untreated PC12 cells and this pool did not change following 6-OHDA treatment. Interestingly, 
translocation of dnJNK1 to the mitochondria after addition of 6-OHDA was observed (Fig. 
3.7 B). Similar to nucleus, inhibition of JNK with SP600125 prevented the translocation of 
JNK2 to the mitochondria, but had no effect on the constitutive presence of JNK1 (Fig. 3.7 
C). Consequently, the pool of activated JNK at the mitochondria was determined. Under basal 
conditions, hardly any phosphorylated JNK could be detected at the mitochondria. After 
stimulation with 25 µM 6-OHDA, the amount of phosphorylated JNK increased at the 
mitochondria within 4 h and returned to basal levels until 48 h after stimulation (Fig. 3.7 D). 
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Fig. 3.7. Translocation of JNKs into the mitochondria 
A. JNK2 translocated to the mitochondria after 6-OHDA treatment under all experimental conditions. 
The EGFP-tagged dnJNK2 was not present at the mitochondria. B. In contrast to increasing levels of 
JNK2, JNK1 levels did not change after addition of 6-OHDA at the mitochondria. C. Pre-incubation 
of PC12 cells with SP600125 inhibited the translocation of JNK2, but not JNK1, into the 
mitochondria. D. Levels of phosphorylated JNK (p-JNK) were increased in mitochondrial preparations 
between 4 h and 24 h after 6-OHDA stimulation while total JNK protein (tJNK) did not change. n = 4. 
co, unstimulated. wt, wild type  
 
3.1.5. Upstream kinases and scaffolds of JNKs at the mitochondria 
 
A substantial amount of MKK4 was detected at the mitochondria from untreated cells. 
Stimulation of the cells with 25 µM 6-OHDA activated the mitochondrial MKK4 pool within 
1 h and its activation reached its maximal levels between 2 h and 4 h. Transfection of the cells 
with dnJNK2 abrogated the phosphorylation, but not the presence of MKK4, while 
transfected dnJNK1 had no effect (Fig. 3.8 A). Additionally the JNK-inhibitor SP600125 
prevented the phosphorylation of MKK4 at the mitochondria (Fig. 3.8 B). In contrast to 
MKK4, MKK7 was not detected at the mitochondria, while it was detectable in cytoplasmic 
extracts (Fig. 3.8 C). The JNK scaffold protein JIP-1 was present in mitochondrial 
Results 
 
 53
preparations and its expression did not change after stimulation with 6-OHDA (Fig. 3.8 C) 
underlining the specificity and selectivity of the observed localization and activation of JNK 
signalosome components. The presence of only weakly phosphorylated JNK at the 
mitochondria suggests the presence of mitochondrial phosphatases which de-activate JNKs. 
Therefore, MAP kinase phosphates 7 (MKP7) which was recently identified as a major and 
JNK-specific phosphatase was investigated [88]. Indeed, MKP7 was detectable at the 
mitochondria and in the cytoplasm and its expression did not change after 6-OHDA (Fig. 3.8 
C). 
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Fig. 3.8. Upstream kinases and the scaffolds of JNKs at the mitochondria 
A. In mitochondrial preparations, MKK4 protein was detected in all cells which was phosphorylated in 
response to 25 µM 6-OHDA. However, dnJNK2 inhibited this phosphorylation. B. Similar to dnJNK2, 
pre-incubation with SP600125 blocked MKK4 phosphorylation. C. MKK7 was not present at the 
mitochondria, while JIP-1 and MKP7 were present at the mitochondria.  
n = 4. co, unstimulated. 
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3.1.6. Cytochrome c release, caspase-3 activation and regulation of bim  
 
Twenty-five µM 6-OHDA caused a strong depletion of mitochondrial cytochrome c which 
was inhibited by pre-incubation with 2 µM SP600125 in wild type and vector controls. 
Similar to SP600125, transfection of the cells with dnJNK2 reduced cytochrome c release in 
response to 25 µM 6-OHDA. However, dnJNK1 had no effect on cytochrome c release (Fig. 
3.9). 
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Fig. 3.9. Release of cytochrome c 
Twenty-five µM 6-OHDA induced cytochrome c release from mitochondria. Pre-incubation with 
SP600125 inhibited the release of cytochrome c. DnJNK2 had similar effects as SP600125 while 
dnJNK1 had no effect. co, unstimulated. wt, wild type. 
 
 
To investigate the function of JNK2 in apoptosis induced by 6-OHDA, caspase-3, PARP-1 
and caspase-8 cleavage was examined. 6-OHDA induced caspase-3 and PARP-1 cleavage, 
which was inhibited by incubation with SP600125 (Fig. 3.10 A) or transfection with dnJNK2 
(Fig. 3.10 B). As expected dnJNK1 had no effect on caspase-3 or PARP-1 cleavage (Fig. 3.10 
C). Caspase-8 cleavage was not seen either in wild type or in dnJNK2 cells (Fig. 3.10 A and 
B), indicating the importance of the mitochondrial pathway in 6-OHDA-induced apoptosis. 
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Fig. 3.10. Activation of apoptotic mediators 
A. Twelve hours after 6-OHDA stimulation caspase-3 and PARP-1 cleavage was seen in vector 
controls. This activation was attenuated by SP600125 B. The cleavage was blocked by dnJNK2, C. 
but not with dnJNK1. Caspase-8 cleavage was not detected under any conditions, although a strong 
expression was detected. co, unstimulated. 
 
 
Finally, in order to investigate bim regulation in response to 6-OHDA-induced apoptosis, bim 
mRNA levels were analyzed by semi-quantitative RT-PCR. Eighteen and 24 h after 25 µM 6-
OHDA stimulation, bim did not increase beyond/over basal level. However, dnJNK2 
markedly reduced bim mRNA after 18 h and 24 h 6-OHDA stimulation (Fig. 3.11). 
 
 
 
– 200 bp
bim
co 18 24h
25 µM 6-OHDA
h2a.z
wildtype
– 200 bp
bim
h2a.z
dnJNK2
– 300 bp
– 300 bp
 
 
Fig. 3.11. Regulation of bim 
Bim expression was not induced within 24 h. DnJNK2 reduced bim expression between 18 h and 24 h. 
h2a.z, histone 2A as control to normalize bim measurement. co, control. 
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3.1.7. The effect of JNK3 on 6-OHDA-induced toxicity 
 
PC12 cells only express JNK1 and JNK2 [22, 89] and this property renders PC12 cells a well-
defined cell culture system for the analysis of a single transfected JNK3 isoform. Therefore, 
PC12 cells were transfected with JNK3-EGFP and the functional potential of JNK3 in 6-
OHDA-induced toxicity was characterized. 
 
To examine if JNK3 had any influence on 6-OHDA-induced cell death, JNK3-transfected 
PC12 cells were stimulated with 25 µM and 50 µM 6-OHDA for 24 h. There was no increase 
in cell death of JNK3-transfected cells after treatment with 6-OHDA compared to wild type 
and vector-transfected cells (Fig. 3.12). 
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Fig. 3.12. Survival of wild type, vector-transfected and JNK3-transfected cells after stimulation 
with 6-OHDA 
In response to 6-OHDA survival of PC12 cells was reduced as compared to controls. The survival of 
JNK3-transfected cells was not significantly different from wild type or vector-transfected cells. n = 6.  
 
As shown in section 3.1.2, 6-OHDA induced a dose-dependent phosphorylation of total JNK 
in wild type and vector-transfected cells. Following JNK3 transfection, 6-OHDA caused a 
similar activation of JNK3 in cytoplasmic extracts. Interestingly, JNK3 was not activated in 
nuclear extracts while JNK1 and JNK2 were activated. However, JNK3 was present in the 
nucleus in untreated and 6-OHDA-stimulated cells (Fig. 3.13 A). Similar to wild type cells, 6-
OHDA induced translocation of JNK2, but not JNK1, into the nucleus in JNK3-transfected 
PC12 cells. Transfection with JNK3 did not enhance c-Jun phosphorylation compared to wild 
type after 6-OHDA stimulation (Fig. 3.13 B). 
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Fig. 3.13: Activation of JNK3 in response to 6-OHDA. 
A. Transfected JNK3 was activated after 6-OHDA treatment in the cytoplasm. JNK3 was not activated 
in the nucleus although it was translocated to the nucleus. B. Both wild type JNK1/2 and transfected 
JNK3 were activated in response to 6-OHDA in whole cell extracts, but transfection with JNK3 did 
not enhance c-Jun phosphorylation compared to wild type after 6-OHDA stimulation. 
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3.1.8. Differentiation protects PC12 cells against 6-OHDA-induced death 
 
When treated with NGF, PC12 cells differentiate into neuron like cells [86]. To investigate 
the influence of 6-OHDA on differentiated PC12 cells, they were treated with 50 ng/ml NGF 
for 7 days and stimulated with different concentrations of 6-OHDA for 24 h. In contrast to 
naïve PC12 cells, differentiated PC12 cells were resistant to 6-OHDA-toxicity. Twenty-five 
µM and 50 µM 6-OHDA did not provoke cell death in differentiated PC12 cells (Fig. 3.14 A). 
Interestingly, in contrast to its protective effects in naive cells, the specific JNK-inhibitor 
SP600125 induced cell death either in unstimulated (controls) or stimulated differentiated 
PC12 cells (Fig. 3.14 B). 
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Fig. 3.14. 6-OHDA did not induce cell death in differentiated PC12 cells 
A. PC12 cell were treated with 50 ng/ml NGF and stimulated with different concentrations of 6-
OHDA. Only 100 µM 6-OHDA induced significant cell death. B. Stimulation of differentiated PC12 
cells with 2 µM SP600125 induced cell death either in controls or in 6-OHDA-stimulated cells.  
 +++ gives the significance of changes compared with controls for p ≤ 0.001. co, unstimulated. n = 3.  
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3.2. JNKs and death of primary neuronal cells 
 
The aim of the second part of this study was to investigate the role of JNKs in the death of 
primary neurons. Two kinds of primary neuronal cultures, hippocampal and cortical cells, 
were grown from newborn rats and mice. 
 
3.2.1. Characterization of hippocampal and cortical neurons  
 
The hippocampal and cortical neurons were cultured for six days. The culture condition 
resulted in a mixed cell population with less than 20% astroglia cells and more than 80% 
neurons. Neurons were identified with the neuronal marker MAP-2 (microtubule associated 
protein 2) staining. In undifferentiated neurons MAP-2 is present in the axons, dendrites and 
the cell body. With subsequent development, MAP-2 vanishes from the axons, but remains in 
the dendrites and the cell body [90]. Astrocytes were identified with the astrocyte marker 
GFAP (glial fibrillary acidic protein) staining. Double staining of the cell cultures with MAP-
2 and GFAP showed the interaction between astrocytes and neurons (Fig.3.15). 
 
 
MAP-2+GFAP
 
Fig. 3.15. Double staining of the cells with MAP-2 and GFAP 
Arrows indicate neurons (blue) and arrowheads indicate astrocytes (brown). Magnification 200X. 
 
The following figures display hippocampal and cortical neurons and astrocytes in the culture. 
Immunofluorescence staining showed the typical characteristics of astrocytic and neuronal 
nuclei which are bigger in astrocytes and smaller in neurons. Nuclei were stained with 
Hoechst dye (Fig. 3.16). 
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Fig. 3.16. Hippocampal and cortical neurons in the culture 
A. Hippocampal and cortical neurons in the culture. Nuclei were stained with Hoechst dye (blue) and 
neurons were stained with MAP-2 (red). B. Astrocytes were stained with GFAP (red). Arrow indicates 
astrocytes in the culture and arrowheads indicate nuclei of hippocampal neurons. Magnification 200X. 
 
 
 
 
 
Results 
 
 61
3.2.2. Glutamate-induced death of primary hippocampal neurons 
 
L-glutamic acid is the principal excitatory neurotransmitter in the mammalian central nervous 
system and plays a crucial role in plasticity and toxicity of certain neuronal cells [91]. To 
examine whether JNKs are involved in the glutamate-induced excitotoxicity of neuronal cells, 
primary hippocampal cells from newborn rats (up to 24 hours) were isolated. 
 
Five days after plating the cells (DIV 5), the mixed neuronal cultures were stimulated with 
glutamate for 24 h and then stained with MAP-2. The density of neurons in untreated cells 
was counted and set as 100%. The neurons lost their MAP-2 immunoreactivity (IR) and the 
number significantly decreased to 66% after glutamate treatment. To investigate the role of 
JNKs on glutamate-induced cell death, mixed hippocampal cultures were pre-incubated with 
SP600125, the specific JNK- inhibitor, 30 min before glutamate treatment which rescued 56% 
of the otherwise dying neurons. This suggests that JNK pathway could be involved in 
glutamate-induced neuronal death (Fig. 3.17). 
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Fig. 3.17. Protection of hippocampal neurons by SP600125 against glutamate 
Glutamate caused significant cell death in neurons as compared to unstimulated controls (co) after 24 
h stimulation. Loss of neurons was indicated by the decrease of MAP-2 immunoreactivity. Pre-
incubation of mixed hippocampal cultures with 2 µM SP600125 significantly protected neurons from 
glutamate toxicity. Controls were defined as 100%. +++ gives the significance of changes compared 
with controls for p ≤ 0.01.  *** gives the significance of changes by SP600125 compared with 250 µM 
glutamate-treated cells for p ≤ 0.05.  n = 6. 
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As described above, only 66% neurons were alive after 24 h glutamate exposure. However, 
these surviving neurons exhibited morphological signs of severe cell stress such as short 
dendrites and vacuolated cytoplasm in comparison with untreated cultures (Fig. 3.18). 
 
 
 
 
 
 
 
 
 
 
Fig. 3.18. Morphology of degenerating neurons 
A. Untreated hippocampal neurons with intact continuous neurites and round smooth cell bodies. B. 
24 h after glutamate-treatment, neuronal morphology with short dendrites and vacuolated cytoplasm 
was seen (arrow). Magnification 200X. 
 
 
To determine whether glutamate induces apoptosis in hippocampal neurons, neurons were 
stained with the DNA dye Hoechst 33258 to visualize nuclear morphology. In the absence of 
glutamate, the cultured neurons exhibited normal cellular morphology with evenly stained 
nuclei (Fig. 3.19 A). Glutamate caused morphological changes that are characteristic for 
apoptosis, including fragmentation and condensation of nuclei (Fig. 3.19 B). However, it had 
no effect on astrocytes. 
 
Caspase is considered to play an essential role in the execution stage of apoptosis [92]. 
Activation of caspase-3 requires cleavage of its inactive form (32 kDa) into active p17 and 
p12 subunits [93]. To investigate the influence of glutamate on caspase-3 activation, Western 
blot analysis was performed using a cleaved-caspase-3 specific antibody that recognizes the 
p17 subunit of activated caspase-3. After determining cleaved-caspase-3, blot membranes 
were stripped and rehybrized with antibody against caspase-3 to normalize for protein 
contents. Glutamate stimulation induced caspase-3 activation which was inhibited after pre-
incubation with JNK-inhibitor SP600125 (Fig. 3.19 C). 
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Fig. 3.19. Death of hippocampal neurons induced by glutamate is apoptotic 
Hoechst staining visualizes nuclear morphology. A. Untreated cells. B. Cells treated with 250 µM 
glutamate for 12 h. Arrowheads indicate healthy cells with uniformly stained nuclei. Arrows mark 
neurons with apoptotic morphology including condensed or fragmented nuclei.  Magnification 200X. 
C. Glutamate induced caspase-3 activation in mixed hippocampal cultures. Pre-incubation with 
SP600125 (30 min) inhibited the activation of caspase-3. Western immunoblot probed with antibodies 
to cleaved caspase-3 (top) and caspase-3 (bottom). n = 2. 
 
Regulation of JNK activity in glutamate treated neurons 
 
JNK pathways are essential for apoptosis [58]. To examine the role of the JNK pathways in 
glutamate toxicity, the cells were treated with 250 µM glutamate for 4 h. 
Immunocytochemistry was performed using a specific anti-phospho-JNK and anti-phospho-c-
Jun antibody. In untreated cells, phosphorylated-JNK was concentrated in the nucleus and the 
varicosities of the neurons and astrocytes. After glutamate treatment the phosphorylated-JNK 
immunoreactivity faded out in the varicosities and the nucleus of the neurons while the JNK 
activity persisted in astrocytes (Fig. 3.20 A and B). However, in untreated cells, 
A 
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phoshporylated-c-Jun was hardly seen, but it increased slightly after glutamate treatment. 
(Fig. 3.20 C and D). 
 
For Western blot experiments nuclear extracts were obtained as described in methods. Equal 
amounts of protein (10 µg) extracts were separated by SDS-PAGE, and detected by anti-p-
JNK and anti-p-c-Jun antibodies. A basal JNK activity was seen in the untreated primary cell 
nucleus while this activation was suppressed after glutamate treatment which was also seen by 
staining of the cells with a specific anti-p-JNK antibody. In untreated cells, c-Jun had little or 
no activity which was increased in the nuclear extracts of primary neurons following 4 h 
glutamate stimulation. Pre-incubation of the neurons with 2 µM SP600125 reduced this 
activation (Fig. 3.20 E). 
 
Results 
 
 65
E
phospho-JNK
phospho-c-Jun
+
-
+
+
250 µM glutamate
2 µM SP600125
co
-50 kD
-50 kD
nucleus
B
D
A
C
 
 
 
Fig. 3.20. Regulation of JNKs after glutamate treatment 
A. Phosphorylated-JNK was concentrated in the nucleus and the varicosities of the neurons and the 
nucleus of astrocytes. B. Phosphorylated-JNK immunoreactivity faded out in varicosities and the 
nucleus of neurons but persisted in astrocytes in cultures stimulated with 250 µM glutamate for 4 h. C. 
Phospho-c-Jun could not be detected in untreated cells. D. Glutamate stimulation increased c-Jun 
phosphorylation. Magnification 200X. E. Equal amounts of protein (10 µg) from mixed hippocampal 
neuron extracts were electrophoresed and immunoblotted with anti-p-JNK and anti-p-c-Jun antibodies. 
JNK had a basal activity in untreated primary cell nucleus while this activation was attenuated after 
glutamate treatment. However c-Jun had a weak basal activation which was increased in the nucleus of 
primary neurons after glutamate stimulation. Pre-incubation of the neurons with 2 µM SP600125 
reduced this activation. 
n = 2. co, unstimulated. 
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3.2.3. 6-OHDA-induced death of primary cortical cells 
 
6-OHDA induced a substantial death in PC12 cells. To investigate the effects of this 
substance on primary neuronal cells, cortical neurons were prepared from newborn rats as 
hippocampal cells. Five days after (DIV 5) plating the cells, cortical cells were stimulated 
with different concentrations of 6-OHDA (25 µM, 50 µM, 100 µM) for 24 h and cell death 
was analysed by measurement of LDH activity. After 24 hours of stimulation 25 µM 6-
OHDA weakly increased the LDH release but the difference was not significant compared to 
untreated cells. Fifty and 100 µM 6-OHDA induced significant cell death after 24 hours of 
stimulation (Fig. 3.21). 
 
 
co 25 10050 µM 6-OHDA
0
0.4
0.8
1.2
1.6
LD
H
 re
le
as
e **
* *
**
LD
H
 re
le
as
e **
* *
**
 
 
Fig. 3.21. 6-OHDA-induced death 
Neuronal death induced by different concentrations of 6-OHDA in mixed cortical neuronal culture was 
analysed 24 h later by measurement of LDH released. Untreated cells (co) were set as 1.0.  *** gives 
the significance of changes compared with the controls for p ≤ 0.001. n = 6. 
 
To determine whether 6-OHDA induces apoptosis in cortical neurons, neurons were stained 
with the DNA dye Hoechst 33258 to visualize nuclear morphology. In the absence of 6-
OHDA the cultured neurons exhibited normal cellular morphology with evenly stained nuclei 
which were scored as healthy, viable neurons. 6-OHDA caused morphological changes 
characteristic of apoptosis, including fragmentation and condensation of nuclei. However, 
13% apoptotic nuclei were also seen in untreated neurons, indicating dissociation and 
cultivation may cause DNA fragmentation in neurons (Fig. 3.22). 
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Fig. 3.22. Nuclear pyknotic morphology in mixed cortical neuronal cultures treated with 6-
OHDA for 24 h 
Neurons 5 days in vitro (DIV 5) were stimulated with 6-OHDA for 24 h and stained with Hoechst 
33258 to show nuclear pyknotic morphology. A. Untreated (control) cultures. B. Cultures exposed to 
50 µM 6-OHDA for 24 hours. Note the typical apoptotic morphology in neurons (nuclear 
condensation). Arrows indicate neurons with normal morphology whereas arrowheads indicate 
apoptotic neurons.  Magnification 200X. C. The proportion of apoptotic nuclei is shown. In untreated 
cultures 13% of cells have apoptotic nuclei. * gives the significance of change compared with controls 
for p ≤ 0.05. + gives the significance of change compared with controls for p ≤ 0.001. n = 5. 
 
 
Regulation of JNKs after 6-OHDA treatment 
 
Glutamate altered the distribution of JNK activity in hippocampal neurons. Does this also 
hold true for cortical neurons following 6-OHDA? Western blot experiments demonstrated a 
distinct basal JNK activity in the cytoplasm and nucleus of untreated cortical neurons. Similar 
to hippocampal neurons, JNK activity of cortical neurons was reduced in the nucleus 
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following 6-OHDA while it did not change in the cytoplasm. Which JNK isoforms are 
responsible for this attenuation of nuclear JNK activity? Western blotting demonstrated the 
translocation of JNK2 into the nucleus of cortical neurons between 1 h and 2 h following 6-
OHDA and the parallel decrease between 2 h and 4 h in the cytoplasm, whereas the JNK1-IR 
faded out in the nuclei. At the same time, 6-OHDA induced the activation of c-Jun and the 
maximal phosphorylation at 2 h coincided with the maximal presence of JNK2 and the 
decrease of JNK1 (Fig. 3.23).  
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Fig. 3.23. JNKs after 6-OHDA treatment 
Western blot experiments against phospho-JNK, phospho-c-Jun, JNK1 and JNK2 after 50 µM 6-
OHDA in nuclear and cytoplasmic extracts. In the nucleus, 6-OHDA induced a distinct 
phosphorylation of c-Jun whereas the pool of the upstream JNK kinases decreased. Analysis of the 
individual JNK isoforms demonstrated that JNK1 slightly declined and JNK2 clearly increased in the 
nucleus. In parallel, JNK2 weakly faded out in the cytoplasm, whereas JNK1 did not change. 
 
SP600125 protects cortical neurons from 6-OHDA-induced death 
 
Previous studies demonstrate that JNKs play an important role in neuronal apoptosis. To 
investigate the role of JNKs in 6-OHDA-induced cortical cell death, the specific JNK-
inhibitor SP600125 was used. Pre-incubation of cortical neurons with the JNK inhibitor 
SP600125 significantly decreased LDH release and diminished the proportion of apoptotic 
nuclei by 40% (Fig. 3.24 A-B).  
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Finally, the influence of 6-OHDA and SP600125 on caspase-3 activation was also 
investigated. The cortical neuronal cultures were pre-incubated with 2µM SP600125 (30 min) 
and stimulated with 50 µM 6-OHDA. Western blot analysis was performed using a cleaved-
caspase-3 specific antibody that recognizes the p17 subunit of activated caspase-3 as 
hippocampal neuronal cultures. Caspase-3 was activated after 12 h of 6-OHDA treatment and 
this activation was attenuated with SP600125 (Fig. 3.24 C). 
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Fig. 3.24. Protection of cortical neuronal cells from 6-OHDA-induced death 
A. Pre-incubation with 2 µM SP600125, protected neurons from 50 µM 6-OHDA-induced death. 
Neuronal death was analysed by LDH measurement. n = 6. B. JNK-inhibitor SP600125 diminished 6-
OHDA-induced apoptotic nuclei. Apoptotic nuclei were visualized by Hoechst 33258 test. n = 5. C. 6-
OHDA induced caspase-3 activation following 50 µM 6-OHDA treatment for 12 hours in mixed 
cortical neuronal cultures. The JNK-inhibitor SP600125 inhibited the activation of caspase-3. Western 
blots probed with antibodies against cleaved caspase-3 (top) and caspase-3 (bottom). n = 3. 
** (p ≤ 0.01) indicates significant difference between 6-OHDA vs. SP600125 and 6-OHDA 
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Effects of JNK isoforms on 6-OHDA-induced apoptosis 
 
JNKs play an important role in 6-OHDA-induced cell death in primary cortical neurons. To 
examine which JNK isoform is responsible from this cell death, primary neurons from JNK1 
and JNK3 ko mice were used. Cell death was measured with LDH assay. Analysis showed 
that 25 and 50 µM 6-OHDA induced death in mouse cortical cells, however there was no 
significant difference between cortical neurons of wt, JNK3 ko and JNK1 ko mice, suggesting 
all JNK isoforms are involved in 6-OHDA-induced neuronal death, however, experiments 
with JNK2 ko have to be performed (Fig. 3.25). 
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Fig.3.25 Effect of JNK isoforms on 6-OHDA-induced cell death 
LDH assay showed that there was no significant change between wt, JNK3 ko and JNK1 ko isoforms 
after 25 and 50 µM 6-OHDA treatment. 
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3.3. Function of JNKs in differentiation of primary hippocampal and cortical neurons 
 
Besides their apoptotic functions, JNKs are important for differentiation of neurons and the 
development of the brain [26]. The aim of the third part of this study was to investigate the 
physiological role of JNKs in neuronal differentiation as visualised by neurite extention. 
 
3.3.1. Effects of the JNK-inhibitor SP600125 on neurite elongation 
 
JNKs are essential for the formation and elongation of neurites in PC12 cells [57, 94, 95]. 
Does this also hold true for primary neurons in which it has been demonstrated a most 
effective execution of apoptosis by JNK?  Hippocampal and cortical cultures were exposed to 
2 µM SP600125 at the 2nd, 3rd or 5th day in vitro (DIV) i.e. following explantation. At DIV 6, 
the cultures were stained with MAP-2 antibody, the lengths of neurites were measured and 
classified in 4 groups (<40, <80, <120 and >120 µm). The inhibition of JNK between DIV 2 
and DIV 3 effectively prevented the neurite elongation in primary hippocampal neurons as 
shown by MAP-2 immunocytochemistry (Fig. 3.26 A-B). Measurement of the neurite length 
demonstrated a significant shift from long to short neurites with 89% and 57% of <40 µm 
neurites when SP600125 was applied within the first 48 h or 72 h respectively. (Fig. 3.26 C).  
To examine If JNK inhibitor SP600125 has some effect on neuronal survival, the 
hippocampal cultures were stimulated with 2 and 10 µM SP600125 at the 2nd day and the cells 
were stained with the DNA dye Hoechst 33258 to visualize nuclear morphology at the 6th day. 
Analysis showed that 2 µM SP600125 had not any effect on neuronal survival and JNK 
inhibition has a specific effect on neuritogenesis. However, 10 µM SP600125 raised the 
apoptotic nuclei slightly, indicating that higher concentrations of SP600125 may have toxic 
effects (Fig.3.26 D). 
 
 In contrast to rat hippocampal neurons, JNK inhibition by SP600125 did not significantly 
affect neurite elongation in cortical neurons apart from an increased proportion of short 
neurites after application at DIV3 (Fig. 3.27). 
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Fig. 3.26. Effects of JNK-inhibitor, SP600125 on neurite elongation in hippocampal neurons 
Hippocampal rat neurons were exposed to 2 µM SP600125 at 2nd, 3rd or 5th day in vitro (DIV). At DIV 
6, cultures were stained with MAP-2 antibody. A. Untreated cultures and B. cultures exposed to 
SP600125 at DIV 2 with dramatically abrogated neurites. Magnification 200X.  
C. The distribution of the neurite length (µm) after SP600125 incubation revealed that SP600125 
significantly attenuated the neurite elongation. D. The hippocampal cultures were stimulated with 2 
and 10µM SP600125 at the 2nd day and the cells were stained with the DNA dye Hoechst 33258 to 
visualize nuclear morphology at the 6th day. 2µM SP600125 had not any effect on neuronal survival. 
*, ** give the significant changes compared with the controls for p ≤ 0.01 and p ≤ 0.001, respectively 
(each n=3). co = unstimulated control after cultivation for 6 days. 
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Fig. 3.27. Effects of JNK-inhibitor, SP600125 on neurite elongation in hippocampal neurons 
The effect of the JNK inhibitor SP600125 on neurite elongation of rat cortical neurons was analysed 
by MAP-2 immunocytochemistry. Cultures were exposed to 2 µM SP600125 at 2nd, 3rd or 5th day 
(DIV2, 3, 6) (each n=3). At DIV 6, cultures were fixed and the neurite lengths were measured. 
SP600125 did not affect neurite elongation in neonatal rat cortical cultures.  
 
  
3.3.2. Time course of JNK and c-Jun activation during differentiation 
From the very beginning of regrowth, JNKs are mandatory for the elongation of neurites. 
Does the time course of JNK and c-Jun activation parallel this function? Whole cell extracts 
from mixed rat hippocampal cultures at DIV 2, DIV 3 and DIV 6 were screened by Western 
blotting. The pool of activated JNKs substantially and continuously raised with a maximum at 
DIV 6. Furthermore, the use of individual JNK antisera demonstrated that all three JNK1, 2 
and 3 isoforms moderately increased. In contrast to the increase in JNK activity, the pool of 
phosphorylated c-Jun declined from its maximal level at DIV 2 and faded out at DIV 6 (Fig. 
3.28 A). Thus, the increase of activated JNKs is not automatically indicative for the 
phosphorylation of their nuclear high affinity substrate c-Jun. 
 
JNKs are not mandatory for the neurite elongation of cortical neurons following explantation 
from neonatal rat brain. Is this lack of efficacy reflected by the absence of activated JNKs 
and/or c-Jun? Whole cell extracts from cortical cultures were lysed at DIV 2, DIV 3 and DIV 
6 and screened for total JNK, phosphorylated JNK and phosporylated c-Jun by Western 
blotting. Unexpectedly, the pattern of JNK activation resembled that of hippocampal neurons 
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with a moderate increase in total JNK and a substantial increase in phosphorylated JNK. The 
time course of phosphorylated c-Jun, however, revealed some difference. In contrast to its 
distinct presence after 3 and 6 days in hippocampal neurons (Fig.3.28 A), phosphorylated c-
Jun was completely absent during this observation period (Fig. 3. 28 B). Again, the activation 
of the upstream JNK kinases in whole cell extracts does not automatically indicate the 
phosphorylation of their high affinity substrates such as the nuclear c-Jun. 
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Fig. 3.28. Regulation of JNKs during differentiation 
Time course of activated JNKs and c-Jun during the differentiation of hippocampal and cortical 
neurons.  A. Whole cell extracts from cell cultures at 2, 3 or 6 days in culture were prepared for 
Western blotting for phospho-c-Jun, phospho-JNK, total JNK, JNK1, JNK2 and JNK3. The activated 
phospho-c-Jun declined during the observation period whereas the pool of activated upstream JNK 
kinases was strongly enhanced. This increase was carried by all three JNK isoforms, but in particular 
by JNK1 and JNK2. B. As in neonatal hippocampal neurons, the activation of c-Jun activation 
decreased and in parallel the activation of JNK increased during the differentiation of cortical neurons. 
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4. Discussion 
 
The aims of the present study were to determine the physiological and pathological roles of 
JNK in PC12 cells and in primary neurons by characterizing its activity and expression as 
well as the phosphorylation of its substrate c-Jun. Moreover, I determined the effect of its 
inhibition on cell survival and on neurite outgrowth. Finally, isoform-specific functions of 
JNKs in the mitochondrial apoptosis pathway in PC12 cells were elucidated. 
 
4.1. The cell culture system 
 
In this study, PC12 cells, primary hippocampal and cortical neurons were used for the 
determination of the role of JNKs in physiological or pathological conditions. 
 
The PC12 cell line was cloned in 1976 from a transplantable rat pheochromocytoma [86]. In 
general, PC12 cells exhibit many of the phenotypical properties associated with 
pheochromocytoma cells and their non-neoplastic counterparts, adrenal chromaffine cells. 
Additionally, PC12 cells respond to NGF and, in its presence undergo a dramatic change in 
phenotype wherein they acquire many properties of sympathetic neurons [86]. Importantly for 
this thesis, PC12 cells have fairly well been characterized with regard to their biochemical 
properties. They express only JNK1 and JNK2 isoforms, but not JNK3 isoform [89, 96]. 
These qualities render PC12 cells a well-defined cell culture system for the analysis of the 
pathological role of individual JNK isoforms at the mitochondria and the mode of JNK-
induced release of cytochrome c. 
 
However, some different properties between proliferating and differentiated permanent 
neuronal cells raise the need for the use of primary neuronal cells in this study. Therefore, 
primary hippocampal and cortical cultures were also used. The hippocampus is a source of 
neurons with well-characterized properties typically for central nervous system neurons in 
general [97] and suitable for dissociated cell culture. 
 
Immunocytochemical analysis showed that hippocampal and cortical cultures revealed after 
six day in culture the characteristic properties of the corresponding neurons. Staining with the 
neuronal marker MAP-2 (microtubule associated protein-2) and the astrocyte marker GFAP 
(glial fibrillary acidic protein) identified more than 80% of the cells as neurons in the culture. 
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Very few cells being neither positive for MAP-2 nor for GFAP, were other non-neuronal cells 
such as fibroblasts and endothelial cells. Proliferation of these cells and astrocytes were 
inhibited with cytosine arabinoside (AraC). 
 
In undifferentiated hippocampal or cortical neurons MAP-2 is present in the axons, dendrites 
and the cell body. With subsequent development, MAP-2 vanishes from axons, but remains in 
dendrites and the cell body [90], and this was also characteristic for the development of 
hippocampal neurons in vitro [98]. 
 
4.2. Role of JNK isoforms following 6-OHDA-induced oxidative stress in PC12 cells 
 
The results of the present thesis show that the neurotoxin 6-OHDA, a generator of reactive 
oxygen species (ROS) and activator of mitochondrial stress [99], kills a high proportion of 
PC12 cells within 24 h. JNK2, but not JNK1, was translocated to the nucleus and to the 
mitochondria upon 6-OHDA challenge and mediates 6-OHDA-induced apoptosis. Inhibition 
of JNK activity by SP600125 or transfection with the dominant-negative JNK2 (dnJNK2), but 
not dominant-negative JNK1 (dnJNK1), substantially attenuated 6-OHDA-induced cell death, 
release of cytochrome c and caspase-3 activation. Surprisingly, transfection of PC12 cells 
with EGFP-JNK3 did not enhance cell death induced by 6-OHDA. Interestingly, JNK3 was 
not activated in nuclear extracts while JNK1 and JNK2 were activated. However, JNK3 was 
present in the nucleus of untreated and 6-OHDA-stimulated cells. In contrast to naïve PC12 
cells, 25 and 50 µM 6-OHDA did not induce any cell death in NGF-differentiated PC12 cells, 
and the JNK-inhibitor SP600125 even induced the death of non-stimulated differentiated 
PC12. 
 
4.2.1. JNKs are mediators of 6-OHDA-induced cell death in PC12 cells 
 
The neurotoxin 6-OHDA is a widely used experimental stimulus for the degeneration of 
(dopaminergic) neurons in vivo and in vitro. It mediates cell death via several different 
mechanisms. It is a strong producer of oxidative stress with all its deleterious consequences 
for the cell, e.g. impairing intracellular redox potential regulation, lipid peroxidation, DNA 
strand break (reviewed by [100, 101]). Independent of ROS formation, 6-OHDA interacts 
with and inhibits the complex-I in isolated brain mitochondria [102-104] but the relevance of 
complex-I inhibition for cell death has not yet been proven [105]. Closely related to the 
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mitochondrial pathology is the 6-OHDA-mediated cytochrome c release with subsequent 
activation of caspase-9 and caspase-3, PARP-1 cleavage and DNA fragmentation [106-108] 
(reviewed by [101, 109]). Moreover, protection against 6-OHDA toxicity by NO is mediated 
by the inhibition of cytochrome c release [110]. Beyond generation of ROS and mitochondrial 
dysfunction, 6-OHDA is a strong activator of JNKs [106], but the mode of JNK activation by 
6-OHDA remains to be elucidated. 
 
JNK-mediated neuronal death occurs in response to various stimuli, e.g. growth factor 
withdrawal [111], excitotoxicity [30] or neurotoxins such as MPTP [54, 56]. 6-OHDA caused 
cell death in PC12 cells. Inhibition of JNK activity by 2 µM SP600125 rescued 68% of the 
otherwise dying neurons, and a similar protective effect was reached by dnJNK2, but not by 
dnJNK1. The rescue by dnJNK2 demonstrates that one individual JNK isoform rather than the 
total pool of JNKs is responsible for cell death as already shown for JNK3 [30, 57] and JNK2 
[112]. However, inhibition of JNKs only provided a transient protection against 25 µM 6-
OHDA since SP600125 and dnJNK2 were no longer protective after 48 h and 72 h. These 
data were confirmed by recent findings that the inactivation of JNK3 and the N-terminal 
phosphorylation domains of c-Jun conferred significant but only transient protection against 
6-OHDA-mediated degeneration of dopaminergic neurons in adult mice [57]. Transient 
protection against 6-OHDA was also reported after inhibition of caspases [102]. The pathway 
of cell death induced by 6-OHDA is highly dependent on the concentration of 6-OHDA used. 
At 50 µM 6-OHDA, JNK inhibition either by SP600125 or by transfection with dnJNK2 was 
no longer able to protect the cells at any time point, indicating a shift in the cellular death 
pathway(s). Recently, the role of JNKs for 6-OHDA-mediated death was examined with 
regard to cell death caused by ER stress [107] in response to 40-100 µM 6-OHDA. At higher 
concentrations, 6-OHDA induces a different, i.e. accelerated (necrotic) cell death [113] which 
confirms the findings of the present study. The overload of mitochondrial calcium during 
excitotoxicity can result in spill-over of calcium to the ER with subsequent ER stress-
mediated death [45, 114]. 
 
JNK was activated in response to 6-OHDA within 2 h and reached its maximal levels at 4 h in 
the cytoplasm, nucleus and at the mitochondria. This activation was accompanied by a 
translocation of JNK2 into the nucleus and to the mitochondria, whereas the constitutive 
presence of JNK1 did not change in these compartments. The differential translocation of 
JNK isoforms is a critical element for the understanding of isoform-specific JNK actions. For 
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instance, the nuclear translocation of activated JNK2 and JNK3, but not JNK1, is essential for 
the c-Jun/AP-1 mediated transcription [27]. It is also conceivable that JNK2 translocation into 
the nucleus leading to an increased nuclear JNK activity and the subsequent c-Jun 
phosphorylation enhances the expression of Fas-ligand, which in turn facilitates apoptosis 
[113]. Transfection of PC12 cells with dnJNK2 reduced the pool of phosphorylated JNK in 
the nucleus after stimulation with 6-OHDA and strongly reduced the 6-OHDA-induced 
translocation of endogenous JNK2 to the nucleus while dnJNK1 had not such effect. 
Similarly, JNK-inhibitor SP600125 attenuated the translocation of JNK2, but not JNK1 into 
the nucleus following 6-OHDA treatment. These findings suggest that JNK2 is the active JNK 
isoform which mediates the neurodegenerative effects of 6-OHDA. However, the additional 
JNK inhibition via SP600125 in dominant negative JNK2 cells completely abolished the 
protection obtained by either dominant negative JNK2 or SP600125. This suggests the 
physiological role of JNK1 for the survival of PC12. Indeed, even an anti-apoptotic function 
of JNK1 in non-neuronal cells has been suggested, further complicating the different aspects 
of JNK signalling [87]. 
 
4.2.2. The JNK signalosome at the mitochondria 
 
The specific mitochondrial translocation of JNK2, but not JNK1, raises the question which 
signalling pathways control the JNK translocation to and/or the JNK activation at the 
mitochondria. Phosphorylation of JNKs is a prerequisite for translocation. On the other hand, 
the presence of non-phosphorylated JNK1 and JNK2 in untreated cells argues against 
phosphorylation as an absolute precondition for translocation. Similarly, the inhibition of 
MKK4 phosphorylation by dnJNK2 or SP600125 did not reduce the amount of MKK4 at the 
mitochondria indicating that translocation and phosphorylation can be separate events. The 
unexpected inhibitory effect of dnJNK2 on MKK4 phosphorylation is a novel observation 
which warrants further investigation. However, SP600125 may have some ability to inhibit 
upstream kinases in the JNK pathway [115]. It is well conceivable, and supported by the 
findings so far, that a constitutive pool of MKK4 is present at the mitochondria, part of which 
is activated or replaced with activated MKK4 from the cytoplasmic environment upon 6-
OHDA stimulation. Overexpression of dnJNK2 or treatment with SP600125 could shift the 
equilibrium between active and inactive MKK4 by recruiting an excessive amount of active 
MKK4 from the mitochondria-associated pool after 6-OHDA stimulation, which may result in 
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the observed suppression of the mitochondrial phospho-MKK4 signal in dnJNK2-transfected 
or SP600125 treated cells. 
It was shown that MKK4 and JIP-1 are localized at the mitochondria, whereas MKK7 was not 
detectable in the mitochondrial fraction. This suggests a specific JNK pathway for 
mitochondrial pathology. MKK4 was previously found in mitochondrial fractions from 
cardiomyocytes [116], whereas the presence of JIP-1 and the absence of MKK7 are 
completely novel observations. The absence of MKK7 in mitochondrial homogenates is also 
conceivable with the findings, that the MKK7/JNK pathway is responsible for neuritogenesis 
and neurite regrowth after injury [26, 50]. Furthermore, the co-localization of activated JNK 
with the JNK-binding protein Sab [39] points to specific mitochondrial components of the 
JNK pathway. Sab strongly associated with the smaller JNK splice variants [39], which is in 
agreement with the present finding that activated JNK was almost exclusively found in the 46 
kD band. 
 
4.2.3. JNK2 controls the release of cytochrome c, expression of Bim and activation of 
apoptotic proteins 
 
Cytochrome c released from the mitochondrial transition pore is indispensable for the 
generation of the apoptosome with the subsequent activation of downstream caspases 
(reviewed by [117]). Therefore, the control of cytochrome c release is central to anti-apoptotic 
and apoptotic cellular pathways (reviewed by [118]). JNKs can activate pro-apoptotic 
mediators of the transition pore such as Bax, BAD, BIM, BID or Dp5 [40-42, 46, 118] and 
de-activate anti-apoptotic proteins such as Bcl-2 [39, 43, 118]. Moreover, JNKs mobilize 
Smac/Diablo [45] which is released from mitochondria and inhibits anti-apoptotic proteins in 
the cytoplasm. The release of cytochrome c is tightly linked to the presence and activation of 
JNKs [40, 111], and the JNK-mediated cytochrome c release can involve the nuclear 
activation of c-Jun [25] with the subsequent expression of the pro-apoptotic BH3-only protein 
BIM [25, 46]. 
 
JNK inhibition prevented ischemia-induced mitochondrial translocation of Bax and Bim, 
release of cytochrome c and Smac, and activation of caspase-9 and caspase-3 [119-121]. 
However, the issue of the JNK isoform(s) responsible for cytochrome c release in neuronal 
cells has not been clarified. It was shown in this study that dnJNK2, but not dnJNK1, 
antagonises 6-OHDA-induced cell death, cytochrome c release, caspase-3 and PARP-1 
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activation to a similar, or even stronger, extent as the JNK-inhibitor SP600125. The 
translocation of JNK2 to the nucleus and mitochondria supports the notion that the assembly 
of a selective JNK2 signalosome propagates the mitochondrial pathology (Fig. 4.1). A central 
role of JNK2, but not JNK1, for cellular degeneration was also seen in fibroblasts where 
JNK2 mediates tumor necrosis factor-α-induced cell death via caspase and cathepsine 
signalling [56, 122] and the role of JNK2/3 for neuronal stress in primary cerebellar granule 
neurons was examined [27]. Recently, it was shown that in various cell types including 
fibroblasts, erythroblasts and hepotocytes, JNK2 deficiency leads to increased cellular 
proliferation [123]. However, the role of JNK2 is controversially discussed. JNK2 has been 
implicated in tumor growth and cell proliferation [124, 125], and in response to neurotrophic 
factors [50, 126]. Importantly, SP600125, which prevents the stress-induced alterations in the 
membrane potential [87], blocks the mitochondrial translocation of JNK2, but not JNK1. This 
finding suggests that the intracellular distribution of JNK2 depends on its activation and, by a 
positive feedback mechanism, on activated upstream kinases [127]. It remains to be clarified 
whether the apparently moderate mobility of JNK1 might be due to the absence of this 
feedback loop. 
 
The induction of apoptosis and the activation of caspase-3 by 6-OHDA has been examined in 
several studies [128, 129]. Especially in PC12 cells, it has been shown that 25 µM 6-OHDA 
caused apoptosis, whereas the application of 50 µM 6-OHDA caused necrotic cell death [107, 
130]. Activation of mitochondria independent caspase-8 after addition of 6-OHDA was not 
detected despite a strong expression and this underlines the importance of the mitochondrial 
pathway. In fact, the 6-OHDA-induced activation of caspase-8 seems to be a cell type-specific 
event since it has only been described to occur in MN9β cells and mesencephalic neurons 
[131]. The crucial involvement of JNKs in the mitochondrial stress pathway after stimulation 
with 6-OHDA and its effect on the activation of caspase-3 and the cleavage of PARP-1 has 
not been examined before. However, it is known that JNKs play a role in mitochondrial 
signalling in the context of oxidative stress, where JNK inhibition reduced caspase-9 activity 
[31]. 
 
In addition to the phosphorylation of mitochondria-associated substrates, nuclear JNK2 joins 
the nuclear pool of activated JNKs and subsequently contributes to the transcription of c-
Jun/AP-1 controlled target genes such as BIM [25, 41].On the other hand, SP600125 or 
dnJNK2 distinctly reduce nuclear levels of activated JNKs. Dominant-negative JNK2 
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interfered with the transcription of bim at a delay between 18 h and 24 h, but not between 4 h 
and 12 h. The role of the constitutively present JNK1 for mitochondrial functions remains to 
be defined. JNK1 was recently found in the anti-apoptotic XIAP-TAK1-cascade [87], but the 
link to mitochondria-associated protection is speculative. Moreover, the clear distinction 
between anti-apoptotic JNK1 and apoptotic JNK2 is not a general principle since JNK1 can 
also confer apoptosis by Bcl-2 phosphorylation in immune cells [132]. 
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Fig. 4.1. Effects of 6-OHDA on JNK isoforms at the mitochondria 
The JNK2, but not the JNK1 isoform, mediates the death of PC12 following 25 µM 6-hydoxy-
dopamine. Following translocation to the mitochondria, JNK2 mediates cytochrome c release, 
activation of caspase-3 and PARP-1. 
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4.2.4. The effect of JNK3 on 6-OHDA-induced cell death 
 
From all JNK isoforms, JNK3 in particular has been associated with apoptosis in pathological 
contents, and due to its defined expression, predominantly in neuronal degeneration. Deletion 
of the mouse JNK3 gene caused resistance to excitotoxic glutamate receptor agonist kainic 
acid with reduction in seizure activity and apoptosis of hippocampal neurons [30] as well as 
the resistance to 6-OHDA and nerve fiber injury [57]. JNK3 is likely to contribute to ischemic 
death in prenatal and adult rats [133, 134]. In cortical and cerebellar neurons JNKs hold a 
central role in apoptosis caused by UV irradiation, growth factor withdrawal, ß-amyloid and 
sodium arsenide [135-138], however, it has a minor role in cell death following DNA damage 
[139]. Phosphorylation of c-Jun and activation of JNK3 is important in cell death induced by 
Jnk3 gene [30]. 
 
In the present study, PC12 cells which normally only express JNK1 and JNK2, were 
additionally transfected with JNK3. In these cells 6-OHDA did not enhance cell death and it 
did not increase c-Jun phosphorylation compared with vector transfected cells. JNKs realize 
their degenerative effects at least partially in the nucleus and at the mitochondria. However, 
after transfection with JNK3, 6-OHDA caused a similar activation of JNK3 in cytoplasmic 
extracts, but not in the nuclear and mitochondrial ectracts which could explain the absence of 
enhanced cell death in JNK3 transfected cells. Absence of JNK3 activation in the nucleus did 
not induce influence increase in c-Jun activation indicating that there is a correlation between 
JNK3 activation and c-Jun phosphorylation and also JNK3-mediated degeneration. It was 
recently shown that JNK3-deficiency reduced the increase of c-Jun phosphorylation and 
apoptosis after stressful stimulus [30, 137]. The findings in this study suggest that JNK3 is not 
involved in 6-OHDA-induced death, at least in PC12 cells. The missing apoptotic action of 
JNK3 in PC12 cells not necessarily means that JNK3 is without any function in PC12 cells. It 
was shown that transfected JNK3 significantly enhanced NGF-induced neurite outgrowth in 
PC12 cells [67]. 
 
4.2.5. Differentiation protects PC12 cells against 6-OHDA-induced death 
 
When treated with NGF, PC12 cells differentiate into neuron like cells [86]. In contrast to 
naïve PC12 cells, differentiated PC12 cells did not die following 25 µM and 50 µM 6-OHDA. 
It was recently shown that NGF prevented PC12 cells from MPTP induced cell death by 
suppressing caspase-3 activity [140] and protected PC12 cells against 6-OHDA-induced 
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oxidative stress [141], indicating that NGF has protective effect against excitotoxic stimulus. 
However 6-OHDA induced death also in differentiated PC12 cells at higher concentrations 
such as 100 µM  [142] which is in line with this study. 
 
Inhibition of JNKs with SP600125 induced cell death in either unstimulated or stimulated 
differentiated PC12 cells suggesting that JNKs have different functions in differentiated PC12 
cells than in naïve cells. JNKs may have functions in cytoskeletal regulation. Indeed, JNKs 
are relevant for both, the integrity and/or function of the cytoskeleton and the reception of 
signal emanating from the cytoskeleton. Several cytoskeletal components are JNK substrates 
such as neurofilaments and microtubule-associated proteins (MAPs). MAP-2 and MAP-1B 
polypeptides are hypophosphorylated in Jnk1-/- brains, and this compromised the ability to 
bind microtubules and promote their assembly. These results suggest that JNK1 is required 
for maintaining the cytoskeletal integrity of neuronal cells and is a critical regulator of MAP 
activity and microtubule assembly [60]. In cultured neurons from the intermediate zone, 
activated JNK was detected along microtubules in the neurite processes. Application of a 
JNK-inhibitor caused irregular morphology and increased stable microtubules in processes, 
and decreased phosphorylation of microtubule associated protein 1B, raising a possibility of 
the involvement of JNK in controlling tubulin dynamics in migrating neurons [143]. 
Additionally, it is known that JNKs have also anti-apoptotic functions [87]. It appears that the 
JNK pathways function in a cell-type and stimulus dependent manner, i.e. their different 
components and compositions can play opposite roles e.g. in apoptosis or in differentiation. 
 
4.3. Role of JNKs in degeneration of neurons 
 
4.3.1. Glutamate induced cell death in hippocampal neurons 
 
L-Glutamic acid (glutamate) is the principal excitatory neurotransmitter in the mammalian 
central nervous system. Glutamate does not only mediate excitatory neurotransmission, but is 
also involved in other phenomena such as neuronal plasticity and cell death [91, 144]. Cell 
death induced by glutamate is believed to be involved in neuronal loss associated with both 
acute (e.g. stroke) and chronic (e.g. Alzheimer’s disease) neurodegenerative insults [32, 145]. 
 
In this study, glutamate induced loss of MAP-2 immunoreactivity about 34% in neurons 
confirming previous results [30, 146-149]. Staining of the cells with the DNA dye Hoechst 
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33258 showed that glutamate caused morphological changes characteristic to apoptosis, 
including fragmentation and condensation of nuclei [150, 151]. The absence of any 
morphological changes in astrocytes suggested that glutamate had not any effect on astrocytes 
in concentration which is toxic for neurons. 
 
Caspase is considered to play important roles in the execution stage of apoptosis [92]. 
Activation of caspase-3 requires cleavage of its inactive form (32 kDa) into active p17 and 
p12 subunits [93]. In this study caspase-3 activation is involved in cell death in hippocampal 
mixed neuronal cultures which is in line with the other findings [146, 147, 152, 153]. 
However, activation of caspases following glutamate treatment is still controversially 
discussed even in the same type of neurons [153-155]. Postnatal hippocampal cultures consist 
almost exclusively of neurons and astroglia as seen in this study. Since caspase-3 activation is 
performed with Western blot experiments, this activation may include both neurons and 
astrocytes. However, the absence of any morphological changes in astrocytes following 
glutamate treatment suggests that the caspase-3 activation in response to glutamate is a 
specific neuronal reaction. 
 
JNK-mediated neuronal death occurs in response to various stimuli, e.g. growth factor 
withdrawal [111], excitotoxicity [30] or neurotoxins such as MPTP [54, 56]. Inhibition of 
JNK with SP600125 reduced the MAP-2 loss following glutamate treatment, indicating role 
of JNKs in glutamate induced-death. Inhibition of caspase-3 activation following SP600125 
treatment also demonstrates the JNK-mediated death. However, the involvement of JNKs in 
glutamate-induced toxicity is controversially discussed. In cerebellar granule neurons 
glutamate-induced apoptosis is independent of JNKs [149, 155] and inhibition of JNKs had 
not protective effect [155], whereas JNKs are involved in glutamate-induced toxicity in 
cortical neurons [156], in striatal neurons [157] and in hippocampal neurons [30]. The basis 
for this discrepancy is unclear, but presumably reflects differences in the intensity of stimuli 
and the sensitivity of the cells to glutamate-toxicity. 
 
The presence of high basal JNK activity in hippocampal neurons is in agreement with reports 
of high basal JNK activity in the brain [158]. Basal JNK activity was primarily present in the 
cell bodies, processes and the nucleus. After glutamate stimulation, the level of activated JNK 
dramatically declined from nuclei whereas a proportion of c-Jun was phosphorylated. A 
similar ‘paradox’ was reported in embryonic cerebellar neurons [26] and neonatal microglia 
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[50].  It was recently shown that neuronal stress selectively activates JNK2/3 in the presence 
of constitutive JNK1 activity and this JNK2/3 activity selectively targets c-Jun, which can be 
separated from constitutive JNK1 activity [27]. Nuclear JNK activity mediated the apoptotic 
actions of JNKs [159]. However this does not mean that c-Jun is a mere apoptotic mediator 
[reviewed by [160]]. Subsequently, the phosphorylation of c-Jun cannot simply be used as a 
marker for the nuclear activities of either the total nuclear JNK pool or the presence of 
individual JNK isoforms. 
  
4.3.2. 6-OHDA- induced death in cortical neurons 
 
The neurotoxin 6-OHDA is a widely used experimental stimulus for the death of 
(dopaminergic) neurons in vivo and in vitro. It mediates cell death via several different 
mechanisms as described above (see 4.2). 
 
6-OHDA-induced death in cortical neurons resembles that of PC12 cells. It was recently 
shown that 6-OHDA caused death in cortical neurons [107, 161]. Cell death was measured by 
LDH release in the culture. Since cortical cultures include around 15% astrocytes, cell death 
could also occur in astrocytes. However, staining of the cells with DNA dye Hoechst 33258 
showed that only neurons displayed morphological changes characteristic to apoptosis, 
including fragmentation and condensation of nuclei [150, 151] following 6-OHDA treatment. 
Indeed cortical neurons were found to be more sensitive to oxidative stress than astrocytes 
[162]. 
 
The induction of apoptosis and the activation of caspase-3 by 6-OHDA has been examined in 
several studies [108, 128, 129, 163, 164]. In cortical neurons, activation of caspase-3 
following 6-OHDA was shown before [161, 165] and the results are is in line with those of. 
 
JNK-mediated neuronal death occurs in response to MPTP or 6-OHDA [54-56]. Inhibition of 
JNK with SP600125 attenuated death following 6-OHDA treatment in cortical neurons. 
Inhibition of caspase-3 activation following SP600125 treatment also demonstrates the 
involvement of JNKs in 6-OHDA-mediated death.  
 
Similar as hippocampal neurons, cortical neurons contain high basal JNK activity either in 
nuclear or in cytoplasmic extracts. Under basal conditions JNK1 was present in the nucleus, 
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whereas JNK2 was absent in the nucleus. It was already shown that JNK1 is responsible for 
the high level of basal JNK activity in the brain [27, 58]. The presence of JNK1, but not JNK2 
in the nucleus, could explain the absence of c-Jun activation under basal conditions since 
JNK2 has a higher affinity for c-Jun than JNK1 [7, 8]. 6-OHDA reduces total JNK activity in 
the nucleus whereas it slightly induced c-Jun phosphorylation within 1 h. The presence of 
basal JNK1, the enzyme responsible for the basal nuclear JNK phosphorylation, decreased in 
the nucleus following 6-OHDA whereas JNK2 translocated into the nucleus and activated c-
Jun. The presence of a distinct pool of activated JNK in the nucleus suggests that specific 
compartments of JNK serve different functions in neurons e.g. activation of JNK3, but not 
JNK1 or JNK2, in cortical neurons [136] and activation of JNK2/3 in the presence of 
constitutive JNK1 activity in cereballar granule neurons [27] following stress. 
 
It is generally considered that JNK1 has more physiological and anti-apoptotic roles [60, 87, 
166] whereas degenerative apoptotic actions are attributed to JNK2 or JNK3 [30, 118]. 
However 6-OHDA-induced death in cortical neurons in this study, from wildtype, JNK1 ko 
and JNK3 ko mice were not significantly different suggesting the two isoforms meditate 6-
OHDA-induced death not differently. However, further investigations with neurons from 
JNK2 ko mice are required to decide which JNK isoform is important in 6-OHDA-induced 
death in cortical neurons. 
 
4.4. The role of JNKs in neurite outgrowth 
 
The family of JNKs has also been implicated in neuronal differentiation and 
neurodegeneration [29, 34, 57, 58], reviewed by [160, 167]. Several studies have shown an 
enhanced JNK activation in response to NGF [168, 169] or a decrease in neurite outgrowth 
following inhibition of JNKs or their upstream kinases [170-172]. Inhibition of total JNK 
activity by SP600125 almost completely blocked neurite outgrowth and elongation following 
NGF [94]. JNK inhibition by SP600125 and (D)-JNKI1 dramatically reduced axonal 
outgrowth in explanted or dissociated ganglia [66]. In primary cultures of dopaminergic 
neurons, inhibition of JNKs suppressed the total extent of neurites, the primary neurite length 
and the number of neurites per cell [173]. Similarly, inhibition of JNKs by SP600125 
prevented neurite elongation in primary hippocampal neurons in this study. Interestingly, 
inhibition of JNK by SP600125 did not influence outgrowth of cortical neurons. Some time 
ago, inhibition of JNK activity by SP600125 was reported to increase neurite outgrowth in 
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embryonic cerebellar neurons [26]. Thus, JNK exerts different roles in neurite outgrowth ex 
vivo depending on the neuronal phenotype and/or the stage of differentiation. In consequence, 
the function of JNKs has to be defined for each individual type of neurons and conditions. 
 
During differentiation of hippocampal neurons, total levels of JNK continuously increased up 
to 6 days, the end of the observation period mainly by elevation of JNK1 and JNK2. In 
contrast, a very high activation of c-Jun was seen during the early state of differentiation (on 
DIV 2), however, this activation was reduced at DIV 3.  The relatively increased activation of 
total JNK and the reduced c-Jun activation during differentiation are in agreement with the 
result of an other study [26]. Increased activation of JNK occurred downstream of activation 
of MKK7, suggesting an involvement of MKK7/JNK pathway during differentiation rather 
than MKK4/JNK pathway [26].  It was shown in PC12 cells that JNK2, but not JNK1, was 
activated above basal levels during NGF-induced neurite regrowth after injury. Transfection 
of PC12 cells with dnJNK2 reduced neurite outgrowth [94] and also reduced neurite regrowth 
after injury [174]. Otherwise, treatment of SH-SY5Y cells with retinoic acid induced a strong 
activation of JNK1 and transfection of dominant-negative SEK-1 (an upstream kinase of 
JNK1) into the same cells, inhibited retinoic acid induced neurite outgrowth [175] indicating 
that the effect of JNK isoforms on neurite outgrowth may be cell dependent. 
 
What is the difference between the growth-activities of JNKs in the SP600125-sensitive 
neonatal hippocampal neurons and SP600125-insensitive cortical neurons? In both cell types, 
the explantation induced a similar strong and ongoing JNK activation and a moderate increase 
in total JNK. Thus, the mere activation of JNKs in whole cell extracts is not indicative for its 
contribution to regrowth. However, the pool of activated c-Jun transcription factor was 
distinctly smaller in the SP600125-insensitive cortical neurons as compared with the 
SP600125-sensitive hippocampal neurons. This minor pool of activated c-Jun might underline 
the independence of JNK since c-Jun is imperative for the regeneration of axons in vivo [70] 
and can be linked to outgrowth of axons, dendrites and neurites [57, 69, 176-178]. 
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4.5. Conclusions 
 
The function of JNK in apoptosis is complex, since JNKs mediate differentiation and 
apoptosis. It is clear that JNK or at least one of the isoforms activation can contribute to 
apoptosis induced by certain death insults. A role for JNK in the cell survival signal has also 
been predicted. The diversity of the roles of JNK in the regulation of cell fate most likely 
depends on the initiate signalling cascade and/or the protein pattern expressed by JNK. 
 
The present thesis has provided evidence that JNK2, but not JNK1, is a central mediator of 
cytochrome c release following 6-OHDA-induced death of PC12 cells. JNK2 translocates to 
the nucleus and the mitochondria where it acts downstream of MKK4. Thus, the difference in 
activation and translocation of JNK isoforms suggest the existence of separate apoptotic 
signalosomes. Moreover, this study shows that JNKs are important mediators of neuronal 
death following excitotoxic stimulus in primary neurons. This thesis also demonstrates that 
JNKs have physiological roles besides degenerative roles, and they are important for the 
differentiation of the neurons. 
 
These findings have considerable implications for therapeutic strategies targeting JNK 
signalling in neurodegenerative diseases. Inhibition of JNK may decrease apoptosis which is 
contributed to neurodegenerative diseases such as Alzheimer’s and Parkinson’s diseases, 
however, it could also inhibit the cell-cycle arrest, so might limit the use of antagonists as a 
novel strategy for the therapeutic benefit. 
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5. Summary: Functions of JNK stresskinases in neuronal apoptosis and 
differentiation 
 
The c-Jun N-terminal kinases (JNKs), a subfamily of the mitogen-activated protein kinases 
(MAPKs), are considered as essential signalling molecules for neurodegeneration in the 
mammalian brain. However, they also have physiological functions such as in development, 
differentiation, proliferation and neuroregeneration. The aims of the present study were to 
determine the physiological and pathological roles of JNK isoforms in PC12 cells and in 
primary neurons. 
 
6-Hydroxy-dopamine (6-OHDA) causes death of dopaminergic neurons by mitochondrial 
dysfunction with JNKs as central mediators. The first aim of this study was to analyze the 
contribution of different JNK isoforms to 6-OHDA-induced death of PC12 cells. 6-OHDA 
enhanced total JNK activity in the cytoplasm, nucleus and at the mitochondria. Inhibition of 
JNKs by SP600125 or transfection with dominant negative JNK2 (dnJNK2) substantially 
attenuated 6-OHDA-induced cell death, whereas transfection with dominant negative JNK1 
(dnJNK1) had no protective effect. Following 6-OHDA, JNK2 translocated to the nucleus and 
to the mitochondria, while JNK1 was constitutively present in the nucleus and at the 
mitochondria. JNK inhibition by SP600125 or transfection with dnJNK2 reduced the pool of 
active JNKs in the nucleus, the release of cytochrome c, as well as the cleavage of caspase-3 
and its substrate PARP-1. However, transfection with dnJNK1 had no effect on the release of 
cytochrome c or cleavage of caspase-3 and PARP-1. JNK3 is considered as a stress-specific 
kinase and is not endogenously expressed in PC12 cells. Surprisingly, transfected JNK3 did 
not enhance cell death induced by 6-OHDA. Interestingly, JNK3 which was present in 
nucleus was not activated in nuclear extracts while JNK1 and JNK2 were activated. These 
results suggest that from all JNK isoforms, JNK2 in particular is associated with 6-OHDA-
induced death in PC12 cells. In contrast to naïve PC12 cells, 25 µM and 50 µM 6-OHDA did 
not induce any cell death in NGF-differentiated PC12 cells. However, inhibition of JNKs with 
SP600125 induced death either in unstimulated or stimulated differentiated PC12 cells 
suggesting that JNKs have different functions in differentiated PC12 cells than in naïve cells. 
 
To consider specific neuronal conditions, it was necessary to study with primary neurons. 
Therefore, the second aim of this study was to determine and compare the role of JNKs in 
primary hippocampal and cortical neurons following excitotoxic stimulus. Glutamate and     
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6-OHDA induced death and caspase-3 activation in primary hippocampal and cortical 
neurons, respectively. Inhibition of JNKs with SP600125 rescued these otherwise dying cells 
and inhibited caspase-3 activation indicating JNK-mediated death. Western blotting and 
immunocytochemical experiments revealed that there was a high basal JNK activity in 
primary hippocampal and cortical neurons which is in contrast with PC12 cells. Following 
glutamate and 6-OHDA this basal JNK activation declined from nucleus in hippocampal 
neurons and cortical neurons, respectively. However, stimulus induced c-Jun phosphorylation 
in these cells. 
 
Besides neurodegenerative and pro-apoptotic functions, the family of JNKs has also been 
implicated in neuronal differentiation and development. The analysis of the role of JNKs in 
neuronal differentiation represented the third aim of this study. Hippocampal and cortical 
cultures were exposed to JNK-inhibitor, SP600125, at the 2nd, 3rd and 5th day in vitro. 
Inhibition of JNKs by SP600125 prevented neurite elongation in primary hippocampal 
neurons in this study, whereas cortical neurons were not affected. Increased activation of total 
JNK during differentiation of hippocampal neurons indicated the importance of JNKs in 
neuronal development. 
 
Summarizing, these results provide evidence that JNKs have apoptotic effects after an 
excitotoxic stimulus but in parallel to their apoptotic effects they have also physiological 
functions on neurite formation and elongation in vitro during neuronal differentiation. 
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6. Zusammenfassung: Funktionen von c-Jun N-terminalen Stresskinasen in 
der neuronalen Apoptose und Differenzierung 
 
Die c-Jun N-terminalen Kinasen (JNK), eine Familie der Mitogen-aktivierten Protein Kinasen 
(MAPK), sind nicht nur wichtige Signalmoleküle der Neurodegeneration im Säugergehirn, 
sondern sie besitzen auch bedeutende Funktionen in der Entwicklung, Differenzierung und 
Neuroregeneration. Das Ziel der vorliegenden Arbeit war es, physiologische und 
pathologische Funktionen der JNK in PC12-Zellen und primären Neuronen in verschiedenen 
experimentellen Bedingungen zu klären. 
 
6-Hydroxydopamin (6-OHDA) verursacht Zelltod von dopaminergen Neuronen durch 
mitochondriale Dysfunktion, bei der JNK zentrale Signalmoleküle sind. Die erste Zielsetzung 
der vorliegenden Arbeit war es, den spezifischen Beitrag der JNK Isoformen beim 6-OHDA-
induzierten Zelltod zu analysieren. 6-OHDA verstärkte die Gesamtaktivität der JNKs im 
Cytoplasma, im Kern und an den Mitochondrien. Der Einsatz der JNK-Hemmstoffe 
SP600125 oder die Transfektion mit dominant-negativem JNK2 (dnJNK2) verringerte 
signifikant den Zelltod, während die Transfektion mit dominant-negativem JNK1 (dnJNK1) 
keinen protektiven Effekt hatte. Nach der Gabe von 6-OHDA verschob JNK2 sowohl in den 
Kern als auch an die Mitochondrien, JNK1 hingegen war in beiden Kompartimenten 
konstitutiv präsent. Die Hemmung der JNKs durch SP600125 oder die Transfektion mit 
dnJNK2 reduzierte außerdem die Menge an phosphorylierten nukleären JNKs, die Freisetzung 
von Cytochrom c und die Spaltung von Caspase-3 sowie PARP-1. Die Transfektion mit 
dnJNK1 jedoch hatte keinen Einfluss auf die untersuchten Apoptosemarker. Die generell mit 
Zellstress assoziierte Isoform JNK3, die nicht endogen in PC12-Zellen exprimiert wird, 
verstärkte überraschenderweise nicht den 6-OHDA-induzierten Zelltod in diesen Zellen nach 
Transfektion. Interessanterweise, wurde JNK3 aber in den Kernfraktionen nicht aktiviert, 
während JNK1 und JNK2 aktiviert wurden. Diese Ergebnisse weisen darauf hin, dass 
insbesondere JNK2 den Zelltod nach 6-OHDA vermittelt. Im Gegensatz zu naiven PC12-
Zellen, konnten unterschiedliche Dosierungen 6-OHDA (25 µM, 50 µM) keinen Zelltod in 
NGF-differenzierten PC12-Zellen hervorrufen. Allerdings verursachte die JNK-Hemmung 
mit SP600125 Zelltod in stimulierten und unstimulierten Zellen, was vermuten lässt, dass die 
JNKs in differenzierten Zellen andere, eher physiologische Funktionen haben als in naiven 
Zellen. 
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Um die spezifische neuronale Bedingung zu beacten, war es notwendig, für die weiteren 
Analysen primäre neuronale Zellen aus dem Hippocampus und dem Kortex zu verwenden. 
Das zweite Ziel dieser Arbeit war es, die Rolle von JNKs nach exzitotoxischer Stimulation in 
primären Neuronen zu untersuchen. Dabei riefen Glutamat und 6-OHDA gleichermaßen 
Zelltod und eine Aktivierung von Caspase-3 hervor. JNK-Hemmmung durch SP600125 hatte 
einen protektiven Effekt und verhinderte die Aktivierung von Caspase-3. Insgesamt zeigten 
sowohl Western blots als auch immunozytochemische Färbungen eine hohe Basalaktivierung 
der JNKs in hippocampalen und kortikalen Neuronen im Vergleich zu PC12-Zellen. Die 
Stimulation reduzierte die nukleäre Basalaktivität der JNK in hippocampalen und kortikalen 
Zellen. Allerdings führten beide Stimuli zu einer Phosphorylierung von c-Jun in 
hippocampalen und kortikalen Zellen. 
 
Neben neurodegenerativem und pro-apoptotischem Potential besitzen die JNKs durchaus eine 
Bedeutung für die neuronale Differenzierung und Entwicklung. Die Analyse der JNK-
Funktionen in der Differenzierung von Neuronen war das dritte Ziel dieser Arbeit. Dabei 
konnte in hippocampalen Neuronen eine steigende JNK-Aktivierung im Laufe der 
Kultivierung festgestellt werden. Wurden hippocampale und kortikale Zellen mit dem JNK-
Hemmstoff SP600125 am zweiten, dritten und fünften Tag ihrer Kultivierung behandelt, 
verhinderte die inhibierte JNK-Aktivität das Auswachsen der Neuriten von primären 
hippocampalen Zellen, während kortikale Neurone sich normal differenzierten. 
 
Zusammenfassend zeigen diese Ergebnisse, dass individuelle JNK Isoformen im Rahmen von 
Exzitotoxizität pro-apoptotische Signale vermitteln, jedoch auch physiologische Funktionen 
bei der Neuritogenese in einen Teil der Neuronen wahrnehmen. 
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8. Appendix 
 
8.1. Abbreviations and symbols 
 
A adenine 
ABC avidin-biotin-complex 
AP-1 activator protein-1 
ApoER2 apolipoprotein E receptor-2 
APS ammonium persulphate 
AraC cytosine arabinoside (arabinofuranosylcytosine) 
ASK1 apoptosis signal-regulating kinase-1 
ATF-2 activating transcription factor-2 
ATP adenosine triphosphate 
Aß Beta-amyloid 
A260, A280, A595 absorbance at 260 nm, 280 nm or 595 nm, respectively 
A260/A280 ratio between the absorbance values at 260 and 280 nm 
α anti- (e.g. α-rabbit = anti-rabbit antibody) 
Bcl-2 B cell lymphoma-2 
Bax Bcl associated x protein 
Bad BAD, Bcl2/Bcl-xl-antagonist, causing cell death 
Bak Bcl-2 homologous antagonist/ killer 
Bid BH3 interacting death domain agonist 
Bim Bcl-2 Interacting Mediator of Cell Death 
bp base pairs 
BSA bovine serum albumin (albumin fraction V) 
cAMP cyclic adenosine monophospate 
caspase cysteine aspartate-specific protease 
cDNA complementary DNA 
cdc42 cell division cycle 42 
CD 95 APO-1, Fas 
CEP 
11004/1347 
Cephalon compound  
c-Fos v-fos FBJ murine osteosarcoma viral oncogene homologue 
c-Jun v-jun avian sarcoma virus 17 oncogene homologue 
cm centimeter 
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c-Myc v-myc avian myelocytomatosis viral oncogene homologue  
CNS central nervous system 
CREB cyclic adenosine monophospate response element binding protein 
d day(s) 
DAB diamino-benzidine 
DDW double-distilled water 
DEPC diethyl pyrocarbonate 
DEPC-DDW diethyl pyrocarbonate-treated double-distilled water 
Diablo direct IAP binding protein with low pI 
DLB denaturing lysis buffer 
DMSO dimethylsulfoxide 
DNA deoxyribonucleic acid 
DNAse deoxyribonuclease 
dNTP 2’-deoxynucleoside-5’-triphosphate 
Dp5 neuronal death protein 5 
DIV day in vitro 
dn dominant negative  
dT 2’-deoxythymidine-5’-triphosphate 
DTT dithiothreitol 
ECL enhanced chemiluminescence 
ECM extracellular matrix 
EDTA ethylenediaminetetraacetic acid 
EGTA Ethylene-bis(oxyethylenenitrilo)tetraacetic acid 
EGF epidermal growth factor  
EGFP enhanced green fluorescent protein 
Elk-1 Ets-like gene-1 
ERK extracellular signal-regulated kinase 
Fas fibroblast associated antigen 
FCS fetal calf serum 
Fig. Figure 
FITC Fluorescein-isothiocyanat 
g gram(s) 
×g relative centrifugal force (RCF) 
G guanine 
GAP-43 growth-associated protein-43 
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GFAP glial fibrially acidic protein 
grp-75 glucose regulated protein 75 
G protein guanosine triphosphate binding protein 
GTP guanosine triphosphate 
GTPase guanosine triphosphatase 
h hour(s) 
HEPES N-2-Hydroxyethylpiperazine-N'-2-ethanesulfonic acid 
HRP horseradish peroxidase 
H2A.z histone 2A variant z 
HS horse serum 
ICE interleukin-1β converting enzyme (caspase-1) 
Ig immunoglobulin (e.g. IgG) 
IKAP inhibitor of NF-κB kinase complex-associated protein 
IL interleukin (e.g. IL-1) 
imPT mitochondrial inner-membrane permeability transition 
IR immunoreactivity 
IU international unit(s) 
J Joule 
JDP Jun-dimerizing partners 
JIP c-Jun N-terminal kinase-interacting protein 
JNK c-Jun N-terminal kinase 
JNKK c-Jun N-terminal kinase kinase 
JSAP1 Jun N-terminal protein kinase / stress-activated protein kinase-associated 
protein-1 
kb kilobase 
kDa kilodalton 
ko knock out 
l liter(s) 
LDH lactate dehydrogenase 
LFU laminar flow unit 
M molar (mol/L) 
mA milliamper  
MADD MAP kinase activating death domain protein 
MAP microtubule-associated protein 
MAP mitogen-activated protein 
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MAPK mitogen-activated protein kinase 
MAPKAPK mitogen-activated protein kinase-activated protein kinase  
MAP2K mitogen-activated protein kinase kinase 
MAP3K mitogen-activated protein kinase kinase kinase 
MEF2C myocyte enhancer factor-2C 
MEK mitogen-activated protein / extracellular signal-regulated kinase kinase 
MEKK 
 
mitogen-activated protein / extracellular signal-regulated kinase kinase 
kinase 
MEM minimum essential medium  
mg milligram(s) 
min minute(s) 
MKK mitogen-activated protein kinase kinase 
MKP mitogen-activated protein kinase phosphatase (e.g. MKP-1) 
ml milliliter(s) 
MLK mixed-lineage kinase 
mm millimeter 
mM millimolar (mmol/L) 
MPTP 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
mRNA messenger RNA 
mV millivolt(s) 
µg microgram(s) 
µl microliter(s) 
µm micrometer(s) 
µM micromolar (µmol/L) 
n number of independent experiments per experimental series 
NFAT nuclear factor of activated T cells 
ng nanogram(s) 
NGF nerve growth factor 
nm nanometer(s) 
N-terminal aminoterminal 
p. a. pro analysis 
PAGE polyacrylamide gel electrophoresis 
PARP-1 poly(ADP-ribose) polymerase-1 
PBS phosphate-buffered saline 
PBST PBS with Triton X-100 
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PCR polymerase chain reaction 
PD Parkinson’s disease 
pH potentia hydrogenii (hydrogen ion concentration) 
PI3-K phosphoinositide-3-kinase 
PKC protein kinase C 
PMSF phenyl-methyl sulfonyl fluoride 
PNS peripheral nervous system 
Pro proline 
PVDF polyvinylidene difluoride 
p75NTR p75 (75 kDa) neurotrophin (NGF) receptor 
Rac Ras-related C3 botulinum toxin substrate 
Raf v-raf murine sarcoma 3611 viral oncogene homologue 
Ras rat sarcoma viral oncogene homologue 
RCF relative centrifugal force (×g) 
rmax maximum radius (centrifuge parameter) 
RNA ribonucleic acid 
RNAse ribonuclease 
rpm rotations per minute (centrifuge parameter) 
RPMI-1640 Roswell Park Memorial Institute culture medium 1640 
r.t. room temperature (ca. 20°C) 
RT reverse transcription / reverse transcriptase 
RT-PCR reverse transcription polymerase chain reaction 
s second(s) 
SAPK stress-activated protein kinase 
SB 203580 SmithKline Beecham 203580 
SDS sodium dodecyl sulphate 
SDS-PAGE sodium dodecyl sulphate polyacrylamide gel electrophoresis 
SEK JNK kinase 
Ser serine 
Smac second mitochondria-derived activator of caspase 
SP600125 anthra(1,9-cd)pyrazol-6(2H)-one 
STAT signal transducer and activator of transcription 
T thymine 
TAK1 transforming growth factor-β-activated kinase-1 
Taq Thermus aquaticus 
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TBE tris-boric acid-EDTA buffer 
TBS tris-buffered saline 
TBST TBS with Tween-20 
TEMED N,N,N’,N’-tetramethylethylenediamine 
Thr threonine 
TM melting / annealing temperature of primers 
TNFα tumour necrosis factor alpha 
Tpl-2 tumour progression locus-2 
Tris tris-(hydroxymethyl)-aminomethane 
TrkA tyrosine receptor kinase A (NGF receptor) 
Tyr tyrosine 
U unit (of enzyme activity) 
UV ultraviolet (light) 
v/v volume per volume 
w/o without 
w/v weight per volume 
XIAP X-linked inhibitor of apoptosis 
6-OHDA 6-hydroxydopamine 
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